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GENERAL INTRODUCTION 
Newcastle disease (ND) is an important viral disease of poultry which is a major 
economic concern. It has world-wide distribution and affects a variety of avian species. The 
disease is characterized by marked variation in morbidity, mortality, clinical signs and lesions 
(Alexander, 1991). Newcastle disease is prevented and controlled by vaccination and/or by 
quarantine and slaughter of diseased flocks in confirmed outbreaks (Alexander, 1991). 
Various types of Newcastle disease virus (NDV) vaccines, including live attenuated NOV 
strains, inactivated NDV strains and recombinant vaccines have been used to immunize birds 
(Glisson and Stantley, 1993). The relationship between the immune response that is stimulated 
by vaccination and protection is not clearly established. Some studies have indicated that both 
antibody mediated immunity and cell mediated immunity (CMI) play roles in protection 
against ND (Ghumman and Bankowski, 1976; Meulemans et al., 1986). Serological antibodies 
to NDV have been commonly used for the evaluation of ND vaccination and have been 
related to protection against virus challenges (Beard and Brugh, 1975). Antibodies directed 
towards the surface glycoproteins HN and F have been shown to play a role in neutralizing 
NDV in vitro and in vivo (Meulemans et al., 1986), However, a lack of correlation between 
the serological NDV antibody titer and protection fi-om challenge has been reported (Gough 
and Alexander, 1973). In addition, with regards to protection, the role of antibodies directed 
against other NDV proteins has not been determined. 
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Cell mediated immunity has been demonstrated to be the first immunological response 
following ND vaccination and has been suggested to play a key role in protection (Cannon et 
al., 1988; Ghumman and Bankowski, 1976). It has been shown that early protection following 
vaccination can be demonstrated in the presence of low levels of antibody or in the absence of 
detectable antibodies (Allan and Gough, 1976; Ghumman and Bankowski, 1976; Gough and 
Alexander, 1973). Although the CMI response to NDV has been demonstrated in vaccinated 
birds with M) vaccine (Ghumman and Bankowski, 1976; Marino and Hanson, 1987), little is 
known about its role as a key component in protection. The focus of this research was to 
delineate the role of CMI and humoral immunity in protection against NDV. 
Dissertation Research Objectives 
The primaiy purpose of this research was to evaluate the role of cellular and humoral 
immune responses to NDV in relation to protection. The specific objectives of this study were 
to: (1) develop and implement methodology to evaluate specific NDV cell-mediated and 
humoral immune responses in birds; (2) assess the role of CMI to NDV in protection; and (3) 
assess the role of antibodies to NDV proteins in protection. 
Dissertation Organization 
This dissertation consists of a general introduction, a review of the literature, four 
manuscripts, a general summary, literature cited and acknowledgments. The format of each 
manuscript is presented in the style of the journal Avian Diseases, and is comprised of a 
summary, introduction, materials and methods, results, discussion, references, and 
acknowledgments. Data and results of the statistical analysis for each study are appended at 
the end of each manuscript. The references cited in the general introduction, literature review, 
and the general summary are listed following the general summary. The Ph.D. candidate, 
Anwar Maraqa, was the principal investigator for each study. 
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LITERATURE REVIEW 
Newcastle Disease 
Newcastle disease (ND) is an infectious disease aflfecting domestic and wild birds of 
any age. It is one of the most serious diseases of poultry throughout the world (Alexander, 
1991). 
History 
Newcastle disease was first recognized in Java, Indonesia, in 1926. At about the same 
time, a disease with the same symptoms was observed in England, where it was recognized in 
Newcastle by Doyle, hence the name. Within ten years, the disease had spread to middle 
Korea, Japan, India, the Philippines, East Afiica, and Australia. In 1930 a relatively mild-
respiratory disease in chickens was reported in California, USA. This disease was first called 
pneumoencephalitis but later was shown to be caused by a virus which was indistinguishable 
immunologically fi-om Newcastle disease virus (NDV) (Alexander,, 1991). Within a few years 
numerous NDV isolations that produced either a mild or no disease were made around the 
world. Such isolates were used later as live vaccines. Newcastle disease is now recognized in 
most of the major poultry producing countries. Its virulent form is one of the most devastating 
diseases of poultry, causing 100% mortality in chickens (Kouwenhoven, 1993). No accurate 
estimate is available on the cost of disease to the commercial industry. However, the cost 
would include deaths and loss of production due to clinical disease, the total cost of 
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purchasing and applying vaccines, the cost of eradication and quarantine programs and the 
loss of trade (Kouwenhoven, 1993). 
Etiologic agent 
Classiflcation. Newcastle disease virus is classified in the paramyxoviridae family, 
v^hich includes a number of important human and animal pathogens. The viruses in this family 
are grouped into three genera. The genus Morbillivirus consists of measles, rinderpest and 
canine distemper viruses. The Pneumovirus genus consists of the mammalian respiratory 
syncytial viruses, the mouse pneumonia virus, and an avian pneumovirus associated with 
turkey rhinotracheitis. The Paramyxovirus genus consists of parainfluenza virus type 1 (Sendai 
virus), parainfluenza virus type 2 (Simian virus 5), parainfluenza virus type 3 (shipping fever 
virus), parainfluenza virus type 4, mumps and nine distinct groups of avian paramyxoviruses 
termed PMV-1 to PMV-9 (Nagai et al., 1989). Newcastle disease viruses are grouped in the 
avian paramyxovirus type 1 (PMV-1) serotype on the basis of their antigenic relationship in 
serological tests. Some serological relationships have been demonstrated between NDV and 
other paramyxovirus serotypes, the most significant being the viruses of the PMV-3 serotype 
(Alexander, 1991). 
Properties of the virion. Newcastle disease virus is an enveloped virion of 
pleomorphic shape ranging in size firom 100-300 nm in diameter. The envelope is a lipid 
bilayer derived fi-om the host plasma membrane and has spike glycoproteins embedded in and 
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protruding from it (Nagai et al., 1977). There are two sizes of surface projections, the longest 
(about 8 nm) consisting of a single glycoprotein with both hemagglutination and 
neuraminidase activities associated with it. The smaller glycoprotein is associated with the 
ability of the virus envelope to fiise with cell membranes and to cause the fiision of infected 
cells. All avian paramyxoviruses have a herring-bone nucleocapsid of about 18 nm in diameter 
and a pitch of 5 nm, which may be seen either free or emerging from disrupted virus particles 
(Alexander and Collins, 1981; Nagai et al., 1989; Schied et al., 1972). 
Properties of the genome. The genome of NDV is a linear, single-stranded RNA of 
about 5 X 10® dalton in molecular weight with a negative polarity. Nucleotide sequencing of 
the NDV genome has shown it to consist of 15,156 nucleotides. Genes are arranged in the 
genomic RNA in the follovwng order: 3'NP-PA^-M-F-HN-L. There is a leader sequence at the 
3' end comprised of 53 nucleotides, which is not translated into protein. (Matsumor, 1982; 
Miller and Emmerson, 1988; Nagai et al., 1989). There are two consensus sequences, S and 
E, at the start and end of each gene, which are thought to signal the transcription initiation and 
polyadenylation, respectively (Nagai et al., 1989). 
Properties of the virus proteins. The Newcastle disease virus genome encodes the 
following seven proteins: the nucleoprotein (NP), phosphoprotein (P), V protein (V), matrix 
(M), fijsion (F), hemagglutinin-neuraminidase (EIN), and large (L) proteins (Alexander and 
Collins, 1981; Nagai et al., 1989). The hemagglutinin-neuraminidase (HN) and fusion (Fl, 2) 
glycoprotein are glycosylated and form spiked projections on the lipoprotein envelope of the 
virion (Schied et al., 1972). The hemagglutinin-neuraminidase (HN) is the larger NDV 
glycoprotein and contains both hemagglutinin and neuraminidase activities. It is responsible 
for the initial attachment of the virus particles to the host cell receptor that contains 
neuraminic acid. The virus, however, elutes rapidly by the action of neuraminidase, even at 
low temperatures (4 C). Thus, the pattern of hemagglutination, which is caused by the virus 
binding to the receptor on red blood cells (RBC), is unstable (Nagai et al, 1989). This 
property of agglutinating RBCs, and the specific inhibition of agglutination by antiserum has 
proven to be a usefiil tool in the diagnosis of disease (Alexander, 1991). The role of 
neuraminidase (NA) in inducing virus fusion was addressed by Huang et al. (1980). The 
researchers suggested that the role of NA is to remove neuraminic acid from the primaiy 
cellular receptor following adsorption which allows the cellular and viral membranes to come 
closer together and thus permits membrane fusion. Neuraminidase is also considered 
responsible for removing neuraminic acid fi-om glycoproteins and glycolipids synthesized in 
NDV infected cells (Nagai et al., 1976). 
Fusion (F) protein is a small glycoprotein involved in virus penetration or fusion 
through the host cell membrane or between the plasma membrane of two cells, infected and 
uninfected (Scheid et al, 1974). The fiision protein is considered to be the major determinant 
of the wide-ranging virulence of NDV strains. It is sjntithesized as a precursor, FO, which is 
subsequently cleaved by cellular proteases into F1 and F2, and both are held together by 
disulfide linkages (Scheid and Choppin, 1981). The cleavage generates a new N-terminus of 
F1 which is hydrophobic and conserved among paramyxoviruses. The fusion characteristics of 
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the paramyxoviruses are driven by the interaction of this hydrophobic region with the lipid 
bilayer of the target membrane (Richardson et al., 1980). The importance of the F-cleavage 
event with respect to host range and tissue tropism was indicated by Nagai et al. (1977) who 
examined the F glycoprotein synthesized in a variety of host cell systems infected with virulent 
and avirulent strains. With virulent NDV strains, the cleavage of FO occurred in all host 
systems analyzed. V/hereas, with avirulent strains, cleavage occurred only in embryonated 
hens' eggs, or in cultures of chorioallantoic membrane cells, or cell cultures with trypsin. 
Thus, FO molecules of virulent viruses can be cleaved by a wide range of proteases. However, 
FO molecules in viruses of low virulence were restricted in their sensitivity and these viruses 
grew only in certain host cells (Scheid and Choppin, 1974). 
The M protein is located on the inner surface of the envelope and provides structural 
integrity to the virion. It has a crucial role in virus assembly by locating nucleocapsid 
structures beneath those regions of the plasma membrane in which the F and HN 
glycoproteins are anchored (Mastsumor, 1982). 
Nucleoprotein (jNP), phosphoprotein (P), Large (L) protein and (V) protein are 
associated with the genomic RNA to form a ribonucleoprotein complex, termed the 
nucleocapsid. The NP is the structural subunit of the nucleocapsid and confers helical 
symmetry on the capsid. It is the most abundant viral protein and is responsible for control of 
genomic replication (Hamaquchi, 1983). The phosphoprotein (P) is required for viral RNA 
synthesis (Hamaquchi, 1983). The P gene is transcribed to give two different mRNAs. One is 
a copy of the P gene and leads to normal P protein production. The other has an extra 
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guanosine residue inserted during transcription which leads to production of V protein (Nagai 
et al, 1989). The Large (L) protein has an extremely high molecular weight of > 200 Kd. It is 
the least abundant NDV viral protein and is assumed to play a role, together with the P 
protein, in viral transcription and replication. In addition, the L protein may also be involved in 
methylation, capping, phosphorylation and polyadenylation (Hamaquchi, 1983). 
Replication. Newcastle disease virus generates three different RNA products during 
its infectious cycle, namely mRNA, fiiU length antigenomic RNA and genomic RNA. 
Immediately after penetration, the viral transcriptase complex (L and P proteins) binds to the 
template at the 3' end of the genome and sequentially synthesizes the NP, PA'', M, F, UN, and 
L mRNAs. The transcription is discontinuous by terminating and restarting transcription at 
each of the gene junctions (Hamaquchi et al., 1983). Thus, NP mRNA is the most abundant 
while L mRNA is the least, and this is reflected in the quantities of protein synthesized (Nagai 
et al., 1989). The components of the \'irus protein are assembled at the host cell membrane 
and the mature virus is released by budding (Nagai et al., 1976). 
Cultivation. All NDV strains replicate in embryonated chicken eggs, but vary in their 
capacity and time taken to kill chick embryos. Virulent strains spread quickly throughout the 
embryo and kill it, while less •\arulent strains kill embryos more slowly or not at all French et 
al., 1967). The time required by an isolate to kill embryos (the mean death time, or MDT) is 
related to its pathogenicity. Thus, an indicator of lentogenic, mesogenic and velogenic viruses 
can be made by MDT. Virus titers are also influenced by strain, with the highest titers 
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obtainable by those avimlent strains (Hanson et al., 1974). Newcastle disease virus strains can 
also replicate in a great variety of cells, of both avian and mammalian origin. Infection is 
usually lytic, causing typical cell-rounding (Lancaster, 1966; Reeve et al., 1971; Rott, 1979), 
however, different cell types exhibit marked differences in cytopathic formation. BHK-21 
cells, a baby hamster kidney cell line, display a cytopathic effect (CPE) as a giant syncytium, 
while MDBK cells, a bovine kidney cell line, exhibit CPE as rounding with no syncytium at all. 
Furthermore, the infection of L cells, a mouse fibroblast cell line, results in limited or abortive 
replication with reduced yield and cytopathogenicity (Wilcox, 1986). As a consequence, the 
cell may survive the infection but it will become persistently infected. 
The disease 
Hosts. Newcastle disease has been shown to occur in a variety of avian species. Over 
200 species of birds have been reported to be susceptible to natural or experimental infections 
of NDV. Chickens, turkeys, pigeons and pheasants are more susceptible to NDV than ducks 
and geese, which tend to show few signs of disease even when infected with the most virulent 
chicken pathotypes of NDV (Alexander, 1991). A wide range of captive and free-ranging 
semidomestic and free-living birds, including migratory waterfowl, are susceptible and can be 
primary sources of infection (Kouwenhoven, 1993). Occasionally humans become infected 
with NDV. Newcastle disease virus infection in humans usually causes conjunctivitis but 
sometimes laryngitis, pharyngitis, and tracheitis occur (Kouwenhoven, 1993). 
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Transmission. Chickens infected with ISTDV shed the virus into the environment from 
1 to 3 weeks following exposure (Hanson, 1974). Newcastle disease virus has been isolated 
from samples taken from swabs of oropharyngeal, tracheal, or cloacal excretion (Hanson, 
1974). Virus containing excretions including aerosols can contaminate feed, water, clothing, 
equipment and other objects. Exposure of susceptible birds to any of these sources of virus 
can result in transmission (Tumova et al., 1979). True vertical transmission has not been 
documented, but disease in young chickens may originate from eggs laid by infected parents, 
where the virus contaminates the shell (Lancaster and Alexander, 1975). Newcastle disease 
virus can also cause persistent infections and has been recovered from the tracheas of infected 
birds at 14, 40 and 120 days following infection (Heuschele and Esterday, 1970; King, 1983). 
Pathogenesis. Newcastle disease virus usually enters the body via the respiratory 
and/or the intestinal tract. Following multiplication of the virus at the site of introduction, it 
spreads rapidly to the bloodstream where the virus is carried by the blood to different organs 
(Alexander, 1988). The spread of the virus largely depends on the .strain virulence. While 
lentogenic strains are present only at low titers in the circulation, mesogenic strains spread to 
the kidneys, lungs, bursa, and spleen. Virulent NDV can be found within 22-44 hours in nearly 
all tissues, with the highest titers in the thymus and lowest titers in the muscles and brain (Sing 
and El-Zein, 1973). During the second replication, the virus titer increases again and the 'wrus 
is released into the bloodstream. This is associated with the appearance of general disease 
signs and virus excretion into the environment via feces and respiratory secretions. Virulent 
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neurotropic viruses infect the central nervous system at the same time as the respiratory and 
intestinal tract. Viruses pass the blood brain barrier at an accelerated rate causing severe 
damage to this barrier (Kouwenhoven ,1993). 
Pathotype and pathogenicity. The disease caused by PMV-1 is characterized by 
marked variation in morbidity, mortality, clinical signs and lesions which depends on the age 
of the host, infection route, virulence of the strains, virus dose, co-infection with other 
organisms, environmental stress, viral tropism and host immune status (Alexander, 1988). In 
general, the younger the chicken the more acute the disease. Natural routes of infection (nasal, 
ocular, and oral) appear to emphasize the respiratory nature of the disease while 
intramuscular, intravenous, and intracerebral routes appear to enhance the neurological signs 
(Beard and Easterday, 1967). The clinical signs that have been associated with ND are: 
respiratory distress; diarrhea; nervous signs; depression; edema of the head, face, and wattle; 
and a sudden decrease in egg production together with depigmentation and loss of egg shell 
and albumen quality in layers and sudden death. 
Beard and Hanson (1984) grouped NDV strains and isolates into five pathotypes that 
relate to clinical signs of the disease; (1) viscerotropic velogenic Newcastle disease form 
(WND) - produces an acute lethal infection in which hemorrhagic lesions are prominent in 
the digestive tract; (2) neurotropic velogenic Newcastle disease form (NVND) - causes an 
acute often lethal infection of chickens of all ages and has been characterized by acute 
respiratory and nervous disorders; (3) mesogenic form - is less virulent and may cause 
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mortality occurring in young chickens; (4) lentogenic form - produces mild or nonapparent 
respiratory infections, and commonly used as live vaccines; and (5) asymptomatic enteric 
NDV - an avirulent virus that appears to replicate primarily in the intestinal tract. 
Diagnosis. Since clinical signs of NDV are relatively nonspecific, a diagnosis must be 
confirmed by virus isolation and serology (Alexander, 1991). Virus isolation can be made by 
inoculation of infectious material into the allantoic cavity of embryonated eggs. The virus may 
be isolated firom the spleen, brain, or lungs. The presence of the virus can be detected by 
hemagglutination and can be differentiated from other viruses by hemadsorption and a 
hemagglutination inhibition (HI) test using specific antisera. Determination of virulence is 
essential for evaluating field isolates since lentogenic strains in feral birds are widespread and 
lentogenic strains are commonly used as live vaccines. The mean death time in embryonated 
eggs, the intracerabral pathogenicity index (ICPI) in 1-day-old chicks, and the intravenous 
pathogenicity index (IVPI) in 6-week-old chicks are currently used for virulence assessment. 
The ICPI dose not distinguish viruses of high virulence. The IVPI is usefiil for classifying 
moderately and highly virulent NDV but does not differentiate between low virulence viruses. 
Other techniques have also been used to distinguish between various strains of NDV such as 
plaque type and size, hemagglutinin elution rate, structural polypeptides, oligonucleotide 
fingerprints, and monoclonal antibody typing (Alexander, 1991). 
Serology. Most serological techniques used for the detection of antibodies to viruses 
have been applied to NDV, The hemagglutination inhibition test (HI) has been the 
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conventional method of choice, but in more recent years several enzyme-linked 
immunosorbent assay (ELISA) tests have been developed and used widely for flock profiling. 
Virus neutralization, single radial immunodiffiision and agar gel precipitation tests have also 
been used for measuring antibodies to NDV (Alexander, 1991). 
Prevention and control 
Most countries have regulations directed at preventing the introduction of ND by 
quarantining infected birds or contaminated products. Restrictions may also be imposed to 
prohibit the movement of poultry within specified areas (Glisson and Stantley, 1993). 
Vaccination. Basically, there are three types of commercially available vaccines for 
ND: live vaccines, inactivated vaccines and recombinant vaccines (Glisson and Stantley, 
1993). Types of NDV vaccines and route of administration (eye drop, spray, drinking water 
and/or injection) vary depending on several factors. These factors include the level of maternal 
immunity, the virulence of the endemic NDV of a geographic location, the time between two 
successive vaccinations, and the lifespan of the birds (Alexander, 1988). 
Live NDV vaccines. Live vaccines can be divided into two categories based 
on virulence. More virulent vaccines are classified as mesogenic strains while less virulent 
strains are classified as lentogenic strains. Four mesogenic strains (Herts, Mukteswar, 
Komarov, and Roakin) have been used in many parts of the world but presently their use is 
restricted to areas in Afiica, Southeast Asia and the Middle East where endemic velogenic 
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NDV is prevalent. These vaccines are pathogenic and are not recommended for use in 
chickens less than 8 weeks of age, or older chickens that have not been previously vaccinated 
against MDV (Meulemans, 1988). 
Live lentogenic NDV vaccines are the most widely used. They have been shown to 
have a low pathogenicity in poultry while producing an adequate immune response. Four 
lentogenic NDVs (LaSota, Hitchner Bl, F and V4) have been developed as vaccines. Of 
these, Bl and LaSota are the most widely used. Both of these viruses replicate in the 
respiratory tract and induce local and systemic immunity. LaSota vaccines are more virulent 
and induce a stronger immune response than Bl vaccines. Because of the greater potential for 
LaSota vaccines to cause respiratory disease, they are normally used for boostering NDV 
vaccines in chickens previously immunized with Bl (Eidson and Kleven, 1980). 
More recently, a non-pathogenic NDV has been developed for vaccine use in the 
USA. The VG/GA strain was isolated from commercial turkeys and found to provide 
protection in chickens against the lethal challenge of velogenic viscerotropic NDV (WNDV), 
similar to that provided by the Bl strain (Beard et al., 1993). 
Inactivated vaccines. Inactivated oil emulsions of ND vaccines are found to 
provide uniform and long lasting protection without post-vaccinal respiratory reactions. Since 
inactivated vaccines must be injected, they are used primarily to vaccinate breeders and layers 
that have been vaccinated previously with one or more live NDV vaccines. The humoral 
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immune response to inactivated NDV in breeders and layers is very high and of long duration, 
and provides a high level of maternal antibodies for their progeny (Eidson et al., 1982). 
Recombinant NDV vaccines. The recombinant fowlpox virus, which 
expresses the HN and/or F NDV proteins, has been found to provide protection against 
virulent NDV challenge when it is inoculated intravenously, intramuscularly or by wingweb in 
birds without pre-existing antibodies. However, only partial protection is achieved when the 
vaccines are administered orally or ocularly (Edbauer et al., 1990; Taylor et al., 1990). 
Furthermore, recombinant vaccines expressing the HN and/or F glycoprotein have also been 
reported with a vaccinia virus (W) (Meulemans et al., 1988), a herpes virus of turkeys 
(HVT) (Morgan et al., 1992), and a baculovirus (Nagy et al., 1991). Recently, a recombinant 
fowlpox has been licensed and recommended for use with birds having no pre-existing 
antibodies to NDV. 
Immunity to Newcastle Disease 
Humoral immunity 
The role of humoral immunity against lethal infections of chickens with NDV has been 
reported (Umino et al., 1987; Vasington et al., 1960; Wills and Luginbuhl, 1963). It has been 
found that chickens inoculated with egg yolk or plasma from hyperimmunized birds raised 
against NDV were protected when challenged after three weeks of administration (Vasington 
et al., 1960; Wills and Luginbuhl, 1963). The same protection was found when 9-day-old 
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chickens were passively immunized with hyperimmune serum against NDV (Umino et al., 
1987). Hyperimmune serum was also found to reduce mortality when injected 72 hours after 
infection (Umino et al., 1987). 
The role of antibodies in early protection following vaccination against NDV has also 
been reported. Khare et al. (1976) reported that protective immunity against NDV is due 
primarily to antibodies. Circulating antibodies protect the host from reinfection, starting as 
early as four to six days after infection. In the early phase of vaccination IgM is involved and 
followed by IgG. Titers and protection peak three weeks after vaccination, and then gradually 
decline if there is no boostering. A number of reports have indicated that concurrent outbreaks 
of infectious bursal disease virus (IBDV), which has an immunosuppresive effect in chickens, 
reduces the serological response to ND vaccination as measured by the hemagglutination-
inhibition (EDO t®st. This has also been shown to increase the incidence of ND and prolonged 
virus excretion (Allan et al., 1972; Faragher et al., 1974; Pattsion and Allan, 1974). 
Maternally derived antibodies. Immunoglobulins in birds are deposited into the egg 
yolk and chicks absorb these antibodies into their developing systems. The yolk contains 
mainly IgG which becomes the circulating antibody in the chick, while the albumen contains 
predominantly IgA which is swallowed by the developing chick, thus coating its mucous 
membranes with the IgA (Brierly, 1956; Heller et al., 1977). The levels of passively acquired 
maternal antibodies in the serum of a day-old chick are approximately the same as those found 
in the serum of the hen (Allan et al., 1978). The level of passively acquired maternal 
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antibodies found in young chicks generally declines at a constant rate, and has a half-life of 
approximately 4 1/2 days (Allan et al., 1978). Maternal immunoglobulins (IgG) to NDV have 
also been detected in tears, the trachea and lungs (Russell and Koch, 1993). 
Maternal antibodies play an important role in protecting the chick early in its life. 
Umino (1987) demonstrated that chickens hatched from eggs laid by hens vaccinated with live 
attenuated NDV possessed antibodies to the various components of the virus and were 
resistant to challenges with lethal doses of virulent strains of NDV administered 
intramuscularly. The maternal antibodies were found to interfere with active immunization by 
sequestering vaccine antigens or restricting the replication of vaccinal viruses (Beard and 
Brugh, 1975). 
Local immunity. The development of a local antibody immune response to NDV has 
been demonstrated in both the respiratory and intestinal tracts. After vaccination, both IgA 
and IgG specific to NDV have been found in the trachea, lungs, saliva, lacriminal fluid, the 
Harderian glands and the intestine (Powell et al., 1979; Russell and Koch, 1993). The 
administration of NDV vaccines by the intra-ocular route results in the development of high 
levels of IgM, IgG and IgA antibodies in the Harderian gland and in lacrimal fluids due to 
NDV replication in the Harderian gland (Russell, 1993). 
The importance of a local antibody immune response in protection against infection by 
NDV has been indicated by a lack of correlation between serum antibody concentrations and 
resistance to challenge (Beard and Easterday, 1967). It has been reported that birds with large 
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quantities of passively administered antibodies failed to protect the tracheal epithelium upon 
aerosol challenge (Beard and Easterday, 1967). On the other hand, it has also been 
demonstrated that newly hatched chicks possessing maternal antibodies when immunized by 
eye-drop, were protected against intranasal challenge as effectively as antibody-free chickens 
similarly immunized and challenged (Powell and Aitken, 1979). Furthermore, the vaccination 
of chickens via the airsacs protected them against airsac challenge but not against intraoccular 
challenge (Malkinson and Small, 1977). These results suggest that local immunity may be 
operating in the respiratory tract independently of systemic immunity (Holems, 1979). 
Neutralizing antibodies, mainly IgA and IgG, were found in the bile of vaccinated birds 
(Lee and Hanson, 1975). These antibodies, together with an inhibitory effect of the low pH in 
the gizzard, were found to protect the birds from repeated low levels of ingested virulent virus 
(Kohn, 1958). 
The role of NDV polypeptides in protection. Antibodies directed to the surface 
glycoproteins (HN and F) have been shown to play a major role in neutralizing NDV in vitro 
and in vivo (Merz et al., 1981; Meulemans et al, 1986). Antibodies to the-HN glycoprotein 
were found to inhibit attachment to the cell. host receptor, and inhibit adsorption to 
erythrocytes and neuraminidase activities (Merz et al., 1981). Seven antigenic sites on the HN 
have been identified. Three of the antigenic sites have been found to overlap the other sites. 
Antibodies to each site exhibit specific neutralizing capacities of that site (lorio et al., 1984, 
1989). Meulemans (1986) reported that MAbs with a high virus neutralizing activity directed 
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to one antigenic site delayed vims growth and significantly prolonged survival time, even 
though all the chickens succumbed to infection; however, a combination of these monoclonal 
antibodies neutralized the lethal ND V infection. 
Antibodies directed to the F glycoprotein were found to inhibit the hemolysis of 
chicken erythrocytes and neutralize the effectiveness of the virus (Abenes et al., 1986; Avery 
and Niven, 1979; Merz et al., 1981). Merz et al., (1981) demonstrated the effectiveness of 
anti-F antibodies in vitro in neutralizing paramyxovirus infectivity when the virus and 
antibodies were mixed before infection. The same result was found when anti-F sera were 
added after infection because these antibodies were capable of preventing the spread of 
infection from cell to cell (Merz et al., 1981). Abenes et al. (1986) identified four antigenic 
sites (I-IV) on the F protein molecule. Monoclonal antibodies directed to sites I, II and in 
inhibited both virus-induced hemoylsis of chicken erythrocytes and syncytium formation of 
BHK-21 cells. Umino et al. (1990) reported that MAbs directed to two antigenic sites of the F 
protein completely suppressed virus growth and prevented the death of chickens, although the 
neutralizing activities of these anti-F MAbs were lower than those of anti-HN MAbs. Similar 
findings have also been reported by Meulemans et al. (1986) who demonstrated that 
antibodies directed against the F protein of NDV were more capable of protecting chickens 
against viral challenge than HN antibodies. 
The importance of two glycoproteins (HN and F) as a major target of humoral 
immunity has also been examined by using recombinant Newcastle disease vaccines. 
Protection studies have indicated that 1-day-old-birds with no prior immunity to NDV can be 
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protected against velogenic NDV challenge by vaccination with a recombinant fowlpox virus 
(FPV) (Boursnell et al., 1980; Edbauer et al., 1990; Taylor et al., 1990), a vaccinia virus (W) 
(Meulemans et al., 1988), a herpes virus of turkeys (HVT), or a baculovirus (Nagy et al., 
1991) expressing the NDV HN, and/or F polypeptides (Morgan et al., 1992). The antibody 
titers induced by these recombinant vaccines were low as measured by the HI assay and the 
ELISA (Edbauer et al., 1990; Taylor et al., 1990). 
Cell mediated immunity 
Cell mediated immunity (CMI) and protection from NDV have also been reported 
(Agrawal and Reynolds, 1991; Cannon and Russell, 1988; Ghumman and Bankowski, 1976; 
Lam and Hao, 1987; Marino and Hanson 1987; Perey et al., 1975; Timms and Alexander, 
1977). Ghumman and Bankowski (1976) used a lymphocyte blastogenic transformation assay 
to measure the CMI of chickens. Lymphocyte proliferation occurred as early as the 2nd day 
after a primary or secondary vaccination. It was also found that the degree of lymphoc3rte 
stimulation varied with the antigen used for vaccinating the birds. The highest and earliest 
responses were found in groups vaccinated with live NDV via the intramuscular route, 
whereas the lowest response was detected in groups previously vaccinated by the aerosol 
route. Antibody response in this study was detected five days after vaccination. Ghumman and 
Bankowski concluded that there was no correlation between the CMI and HI antibody 
response. 
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Cutaneous delayed hypersensitivity reactions were observed in chickens after ND 
vaccination and challenge. These reactions were diminished during clinical ND which was 
attributed to the extensive damage of macrophages and lymphoid cells, a characteristic of 
virulent NDV infections (Cheville and Beard, 1972; Turner et al., 1979). 
Timms and Alexander (1977) used a leukocyte migration inhibition test (LMI) to 
assess CMI and its relationship to humoral response following vaccination with both live and 
inactivated ND vaccines. The highest LMI values appeared in birds that had received live 
vaccines while the lowest LMI values were found in birds not vaccinated. While the response 
was found to be higher in birds vaccinated with live vaccines than those vaccinated with 
inactivated vaccines, it was diminished when birds were challenged with live viruses. There 
was no correlation between LMI values and HI titers. Agrawal and Reynolds (1991) also 
reported similar findings. 
Marino and Hanson (1987) used bursectomized chickens to study the role of humoral 
and cellular immunity in vaccinated and challenged chickens. Bursectomized birds that had 
been vaccinated had a lower detectable antibody titer than nonbursectomized vaccinated birds. 
In contrast, the birds had a significantly higher CMI response as estimated by a blastogenic 
assay using specific NDV antigen for stimulation. Both vaccinated bursectomized and non 
bursectomized birds survived the virus challenge, however, the challenge virus was isolated 
fi-om the majority of the vaccinated bursectomized birds until 16 days after the challenge. 
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Cell mediated immunity in other viruses 
There have been a number of reports regarding the importance of the cellular immune 
response in controlling other paramyxoviruses (Bennink et al, 1984; Koszinow^ski and Simon, 
1979; Pemberton et al., 1987; Randall et al., 1988). Randall et al. (1988) demonstrated that 
adoptive transfer of immune splenocytes isolated from mice previously infected with Simian 
vims 5 (SV5) to immunocompromised mice increased the rate of virus clearance. In contrast, 
passive transfer of neutralizing monoclonal antibodies against HN and F glycoproteins of S V5 
did not have a significant effect on the rate of virus clearance. 
The importance of viral glycoproteins as a major antigen for inducing CMI has also 
been demonstrated with the Sendai virus (McGee et al., 1980), respiratoiy syncytical virus 
(Pemberton et al., 1987), influenza virus (Bennink et al., 1984) and measles virus (Wild et al., 
1990). In most cases, cytoxoic T lymphocytes (CTLs) were elicited when the viral proteins 
were incorporated into the plasma membrane. The F and HN proteins of Sendai virus were 
shown to be capable of inducing CTLs when presented to the host animal or isolated 
Ijonphocytes in the phospholipid environment or in a liposome (McGee et al., 1980). 
Internal proteins have also been shown to act as target antigens for inducing cellular 
immune response. Studies on the influenza virus (Townsmed et al., 1984), Sendai virus 
(Melief and Kast, 1987) vesicular stomatitis virus (Yewedell et al., 1986), rabies virus 
(Dietzschold et al., 1987) and the measles virus (Stewn et al., 1987) have shown that 
ribonucleoproteins can induce protective immunity. Evidence has been presented by Melief 
and Kast (1987) that the primary line of defense against Sendai virus infection is mediated by 
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CTL by recognizing the internal MP protein. The immunodominant polypeptide of the NP of 
the Sendai virus has been identified and used successfully to vaccinate mice against virulent 
Sendai virus infection. In addition, the immunization of immunocompetent mice with solid 
matrix antibody antigen (SMAA) complexes, containing either surface proteins or internal 
virus structural proteins, has been shown to induce cell-mediated immune responses that 
enhance the speed of viral clearance. Immunization with SMAA complex (exogenous antigen) 
was found to induce both humoral and cytotoxic T-cell (CDS"') responses (Randall et al., 
1988). Adoptive transfer experiments of splenocytes isolated from mice immunized with 
internal structural proteins to immunocompromised mice have demonstrated that the virus 
could be cleared in the absence of detectable levels of serum neutralizing antibodies (Randall 
et al, 1988). 
Cyclophosphamide 
A tumoricidal agent, cyclophosphamide (CY), has a nonspecific immunosuppressive 
effect. Cyclophosphamide acts as an alkylating agent, causing damage to nucleic acids, 
including breaks in DNA strands, cross-links between two DNA strands and cross-linking 
between DNA and RNA or protein (Bach, 1975). Linking results in a major disruption of the 
DNA function and subsequent interference with normal cell mitosis and kills cells undergoing 
multiplication. Cyclophosphamide appears to be selectively cytotoxic for lymphocytes at 
intermediate doses (Petrov et al., 1971), but it does have some effect on all rapidly dividing 
tissues, such as the cells of the bone marrow and gastrointestinal tract (Bach, 1975). 
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Cyclophosphamide has been used experimentally as an immunosuppressant in 
numerous studies to determine some aspects of the immune response such as the role of cell 
mediated immunity in protection (Corner et al., 1991; Kibenge et al., 1987; Nathanson et al., 
1980; Okoye et al., 1992). The susceptibility of B and T lymphocytes to CY has been studied 
(Eskola and Toivanen, 1974; Lerman and Weidanz, 1970). Early observations in chickens 
revealed that B cells were affected to a much greater extent than T cells, especially when small 
doses were used. It has been reported that CY treatment causes suppression of the primary 
antibody response and a profound deficiency in the humoral immunological fiinction (Lerman 
and Weidanz, 1970; Truk and Poulter, 1972). Eskola and Toivanen (1974) found that CY 
given in ovo caused a long-lasting humoral immunodeficiency when administrated on days 14-
16 or on days 16-18 of incubation. The suppression was reversible, and the functional and 
morphological recovery of the antibody producing organs occurred after 10 weeks. However, 
Abdul-Aziz (1981) observed that the bursa of Fabricious regenerated 35 days after CY 
treatment. The mechanism of CY action is based on destroying lymphoid cells in both central 
and peripheral lymphoid organs that have been seeded with bursa-derived cells during embryo 
development. Cyclophosphamide treatment leaves the bursal reticulum intact and affects only 
the lymphoid cells. In addition, very few germinal centers and plasma cells are found wthin 
the spleen, cecal tonsils or in other lymphoid tissues even after an antigenic stimulation 
(Eskola and Toivanen, 1974). 
When given in large doses, CY could suppress the T-lymphocyte response 
(Winklestein et al., 1972). Cyclophosphamide destroys the lymphoid cells in the thymic cortex 
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and, to some extent, causes depletion of the thymus-derived T lymphocytes in the spleen. 
Stevenson et al. (1980) found that T-helper cells and cytotoxic T cells are more resistant to 
the action of CY than B cells and suppressor T cells. A larger dose of CY is required to 
suppress generation of cytotoxic T cells in mice (Ferguson and Simmon, 1978). Delayed 
hypersensitivity reaction is enhanced due to the elimination of suppresser T cells (Grill and 
Liew, 1978). Most evidence indicates that CY suppresses cell mediated immunity in chickens 
temporarily and regeneration occurs within 2 weeks following treatment (Lerman and 
Weidanz, 1970). 
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A TECHNIQUE FOR INDUCING B-CELL ABLATION IN CHICKENS 
BY IN OVO INJECTION OF CYCLOPHOSPHAMIDE 
Manuscript for submission to Avian Diseases 
A. D. Maraqa and D. L. Reynolds 
SUMMARY 
The effect of cyclophosphamide (CY) treatment in ovo on avian B and T cells was 
studied. Cyclophosphamide was injected in ovo on the 16th, 17th and 18th day of incubation. 
Similarly, control eggs were injected with PBS. Blood samples were collected periodically 
from CY-treated and non-treated birds and were used to measure blood lymphocyte responses 
to the T-cell and B-cell mitogens. Con A and LPS, respectively. Additionally, flow cytometric 
analysis was used to determine the presence of B and T cells in peripheral blood. The results 
demonstrated that CY treatment reduced hatchability by 35-40%, increased mortality by 3-5% 
and induced a significant retardation in the gain of body weight. The majority of deaths 
occurred within two weeks following hatchings. At 2 weeks of age, approximately 50% of 
CY-treated birds were devoid of B-cell mitogenic responsiveness while demonstrating 
significant T-cell mitogenic responsiveness. B-cell responses were observed at 4 and 6 weeks 
from only a small percentage of birds that were originally T-cell responsive and B-cell 
nonresponsive at 2 weeks of age. Flow cytometric analysis of peripheral blood lymphocytes 
revealed that CY-treated birds had significantly less B cells (or were devoid of B cells) than 
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the corresponding nontreated control birds. However, no significant differences in the T-cell 
percentage were observed between CY-treated and CY-nontreated birds. 
Humoral immune response was also evaluated by vaccinating T-cell positive/B-cell 
negative (CY-treated) birds with Newcastle disease vaccine, and comparing them with non 
CY-treated control birds. The results revealed that CY-treated birds did not produce 
detectable antibodies specific for NDV during the first and second week post-vaccination, as 
demonstrated by HE assay. However, antibodies were detected in a small number of CY-
treated birds one week post-booster. Those responding birds were found to be the same birds 
that had subsequently responded to the LPS mitogen on the blastogenesis microassay. This 
study indicates the importance of monitoring the B- and T-cell responses in CY-treated birds 
to identify those birds in which B-cell regeneration may have occurred. 
Keywords: cyclophosphamide, Newcastle disease virus, humoral immune response, 
immunosuppressive. 
Abbreviations: 
B bursa-dependent lymphocyte 
CMF-PBS calcium and magnesium free-phosphate buffered saline 
CMI cell-mediated immunity 
CY cyclophosphamide 
Con A concanavalin A 
HI hemagglutination inhibition 
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LPS lipopolysaccharide 
MTT 3-[4,5-Dimethylthiazole-2-yl],2-5- diphenyltetrazolium bromide) 
MDV Newcastle disease virus 
PBL peripheral blood lymphocytes 
PBS phosphate buffered saline 
SPF specific pathogen firee 
UV-NDV ultraviolet inactivated Newcastle disease virus 
T thymus-dependent lymphocytes 
INTRODUCTION 
Cyclophosphamide (CY), a tumoricidal agent, is a nonspecific immunosuppressant 
agent affecting primarily antibody-mediated immunity (7, 8). It has been used experimentally 
as an immunosuppressant to elucidate some aspects of the immune response such as the role 
of cell mediated immunity (CMI) in protection (6, 9, 12, 13, 15, 16). In the clucken, CY given 
in newly hatched birds leads to severe and permanent deficiency in the humoral immune 
response. Eskola et al. (1974) found that CY given in ovo caused severe humoral 
immunodeficiency when administered on days 14-16 or on days 16-18 of incubation. The 
suppressive effect, however, was found to be reversible and the fiinctional and morphologic 
recovery of antibody producing tissue occurred after 10 weeks following treatment (7, 14). 
Cell mediated immunity was also found to be initially affected, but regeneration of the T-cell 
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response occurred more rapidly. T-cell responsiveness was reported to be suppressed for less 
than two weeks (10, 14). 
The CY method for ablating B cells has been shown to be limited by the early recovery 
of antibody producing organs, thus providing only temporary immunosuppression (1, 12, 15). 
Schlink (1986) reported that CY is not effective in depleting all the B cells and a high dose of 
CY with bursectomy is required for ablating B cells from the immune system. 
The objective of tWs study was to better characterize and describe the procedure by 
which CY induces B-cell ablation when administered in ovo. Such a model may be useful for 
deriving birds devoid of B cells to determine the protective components of the immune 
response in vivo against avian pathogens. The procedure was accomplished by treating chick 
embryos with CY during incubation. After hatching, blood samples were collected and 
evaluated by flow cytometry, blastogenesis response to B- and T-cell mitogens and specific 
antibody response to the Newcastle disease vaccine. 
MATERIALS AND METHODS 
Eggs. Specific pathogen-free (SPF) white leghorn eggs were purchased (Hy-Vac Co., 
Gowrie, lA). Birds that hatched were reared on wire-floored cages for 3 weeks. Feed and 
water were provided ad libitum. The birds were also provided v^ath antibiotics (aureomycin, 
chlortetracycline hydrochloride), 3 gram/liter in water, until they were 2 weeks of age. 
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Medium and reagents. A preparation of cyclophosphamide (CY) (Cytoxan, Mead 
Johnson & Company, Evansville, IN) was obtained in a dry form containing active ingredients. 
An aqueous solution was prepared by reconstituting 2 grams of CY in 100 ml (20 mg/ml) of 
calcium and magnesium-free phosphate-buffered saline (CMF-PBS) and filtered through a 
0.22 |am syringe filter. RPMI 1640 supplemented with 25 mM HEPES and L Glutamine 
(Sigma Chemical Co., St. Louis, MO), penicillin (200 fig/ml), streptomycin (200 jig/ml) was 
used for washing and resuspending cells, diluting the mitogens and antigens, and culturing the 
cells. 
Concanavalin A (Con A; Sigma Chemical Co., St. Louis, MO) was used as the T-cell 
mitogen. An aqueous solution was prepared by dissolving 100 mg in 10 ml of CMF-PBS and 
filtered through a 0.22 |im syringe filter. Con A was used at a concentration of 50 |ig/ml for 
whole blood. Lipopolysaccharide (LPS) from Salmonella typhimurium (Sigma Chemical Co., 
St. Louis, MO) was used as the B-cell mitogen. It was prepared in CMF-PBS as 1 !ig/|.il. All 
stock solutions were dispensed into small aliquots and stored at -20 C until used. LPS was 
used at a concentration of 1 |ig/ml for whole blood response. An MTT (3-[4,5-
Dimethylthiazole-2-yl],2-5-diphenyltetrazolium bromide; Sigma Chemical Co., St. Louis, MO) 
solution was prepared by dissolving 10 mg of MTT in 1 ml of CMF-PBS and solubilized by 
sonication. The solution was then fihered through a 0.45 pim syringe filter and stored at 4 C in 
a dark bottle. The HCl-isopropanoI (0.04 N HCI-isopropanol) solution was prepared by 
adding 40 ml of 1 N HCI to one liter of isopropanol. The HCl-isopropanol was stored at room 
temperature in a light-proof bottle. 
Cyclophosphamide treatment. In the first trial, 164 eggs were injected with CY at 
16, 17 and 18 days of embryonic development. In addition, 30 eggs were injected with 
phosphate buffered saline (PBS). This was done by candling eggs to identify the air sac of the 
embryo. The area of the shell above the air sac was disinfected with 3% tincture of iodine. A 
drill was used to make a small hole in the eggshell. An aqueous solution of CY (0.1 ml, 20 
mg/ml) was injected into the air cell membrane by inserting a 25-gauge, 5/8-inch (16 mm) 
needle attached to a syringe. The hole was then sealed with transparent tape and the eggs 
were returned to the incubator. The same procedure was used to inject the control eggs with 
CMF-PBS at day 16 of incubation and on the two succeeding days. The same procedure was 
repeated in the second trial in which 144 eggs were injected with CY and 50 eggs were 
injected with CMF-PBS. 
Virus. The lentogenic strain Bl, B1 of Newcastle disease virus (NDV) was 
propagated in 9-day-old embryonated SPF eggs. Embryonated eggs were inoculated by the 
chorioallantoic route and incubated for 5 days at 37 C. The allantoic fluid was harvested and 
clarified by centrifligation at 3000 x g for 30 minutes. The virus was purified and concentrated 
from the allantoic fluids (see below). The purified virus was then inactivated by exposure to 
ultraviolet light for 40 minutes and evaluated to assure loss of infectivity in embryonic eggs. 
The inactivated NDV was used as an inoculum at 40 |j,g per bird. 
Virus propagation and purification. Newcastle disease virus purification was based 
on the method of Alexander and Collins (3). The Bl strain of NDV was grown in 9-day-old 
embryonated chicken SPF eggs. The embiyonated eggs were inoculated by the chorioallantoic 
route and incubated for 5 days at 37 C. The allantoic fluid was harvested and clarified by 
centrifiigation at 3000 x g for 30 minutes. The virus was pelleted by centrifugation at 50,000 
X g for two hours. The pellet was resuspended in 0.01 M Tris-NaCl pH 7.2 and applied to a 
discontinuous sucrose gradient made from 14 ml 50% w/v and 21 ml 20% w/v in 10 mM Tris, 
0.1 M NaCI, 1 mM EDTA, pH 7.4. Following centrifugation for 2 hours at 50,000 x g, a 
virus band was observed at the sucrose gradient interface. The virus band was collected and 
pelleted at 50,000 x g for 2 hours. The pellet was resuspended in PBS. The purified virus was 
assayed for total protein concentration by Bio-Rad assay (Bio-Rad Laboratories, 2000 Alfred 
Nobel Dr., Hercules, CA 94547), and the purity was assessed by Coomassie blue-stained 
polyacrylamide gel electrophoresis. 
Whole blood. Whole blood was collected from the wing vein of the chickens using a 
syringe containing heparin (20 unit/ml). The whole blood was used for the colorimetric 
blastogenesis microassay. 
Colorimetric blastogenesis assay. The procedure for the blastogenesis microassay 
was performed similarly to that previously described (11). Briefly, the assay was carried out in 
96-well flat-bottomed tissue culture plates (Coming Laboratory Sciences Co., Coming, NY). 
Two hundred microliters of RPMI1640 containing Con A 50 (ig/ml or LPS 1 fig/ml or media 
without mitogens (control wells) were dispensed in each well. Ten microliters of whole blood 
were added in each well. The plate was incubated at 37 C for 93 hours in a humid atmosphere 
of 5% CO2. At 93 hours of the incubation period, 20 [il of MTT (10 mg/ml) were added in 
each well and the plate was reincubated for three hours. At 96 hours of incubation the plate 
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was centrifuged at 1000 x g for 10 minutes at room temperature. The supernatant was 
removed carefiilly and 150 jal of a 10% saponin solution were dispensed into each well of the 
plate to lyse the cells. The plate was shaken for 20 minutes on a plate shaker (mini-orbital 
shaker, Bellco Biotechnology, Vineland, NJ) and the cells were thoroughly resuspended by a 
multiple pipetting with a micropipetter. The plate was centrifuged at 1000 x g for 10 minutes 
and the supernatant was carefully removed. One hundred seventy-five ml of IN HCl-
isopropanol were added to each well to dissolve the formazan crystals and the plate was 
shaken, resuspended and centrifuged as above. One hundred microliters of supernatant were 
transferred to the corresponding wells of a new 96-well plate. The absorbance of each well 
was measured using a micrptiter ELISA reader (Model EL310, BIO-TEK Instruments, Inc., 
Winooski, VT 05404) at a wavelength of 550 nm. 
Flow cytometric analysis. An anti-CD3 mouse monoclonal antibody (MAb) 
(Southern Biotechnology Associates, Inc., Birmingham, AL 35226) was used at 1:200 
dilution. Anti-mouse IgG (Fc specific) conjugated to fluorescein isothiocyanate (FITC) 
(Sigma Chemical Company, St. Louis, MO), was used at 1:500 dilution. Anti-mouse IgM 
polyclonal antibody (FC specific) conjugated to FITC (Nordic Immunological Laboratories, 
Drawer, Capistrano Beach, CA 92624-0517) was used at a concentration 1:200. The single 
color staining method was used to stain T and B lymphocytes as described by Chan et al. (5). 
Briefly, three milliliters of blood were collected from each chicken by venipuncture in a 
syringe containing 20 units/ml of herpin. The blood was diluted 1:1 with CMF-PBS. Then it 
was layered on Lymphoprep™ (Accurate Chemical & Scientific Corporation, Westbury, NY) 
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and centrifuged at 800 x g for 15 minutes at room temperature. The cellular band at the 
medium/Lymphoprep™ interface was collected and washed twice with CMF-PBS. The viable 
lymphocytes were counted by trypan blue dye exclusion after the addition of a 10 nl solution 
of trypan blue in 90 |j.l of physiological saline (0.15 M NaCl). After the cell concentration was 
adjusted to 5 x 10® lymphocytes/ml in CMF-PBS, 200 |il of purified lymphocytes were added 
into each of three 1.5 ml microfuge tubes. The first tube contained 200 |il of diluted anti CDS 
MAb, the second febe contained 200 jil anti-mOuse IgM conjugate FITC and the third tube 
contained CMF-PBS (negative control). The three tubes were incubated for 30 minutes on 
ice. Following incubation, 200 |a,l of CMF-PBS were added to each tube and then the tubes 
were centrifuged at 500 x g for 5 minutes. The supernatant was discarded and 200 jil of anti-
mouse IgG conjugated FITC were added only to the tubes containing anti-CDs and 
reincubated for 30 minutes on ice. After the incubation period these tubes were rinsed as 
before. The remaining cells were rediluted to the final volume of 200 \i\ in CMF-PBS. The 
staining percentages for each sample preparation were determined by flow cytometric analysis 
on a profile (Coulter Corp., Hialeah, FL). 
Hemagglutination inhibition (HI) test. The hemagglutination inhibition test was 
performed as described (4). Briefly, twofold serial dilutions of serum were made in a 96 well, 
round-bottom microtiter plate containing 50 |il of PBS in the first row and 50 lal of NDV 
antigen (10 HA units) in the remaining 11 rows. Serum dilutions ranged from 1:2 to 1:2048. 
The antigen serum mixture was incubated for 30 minutes at 37 C. Then, 50 |il of a 0.05% 
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turkey eiythrocyte suspension were added to each well and reincubated for 30 minutes. A 
positive serum, a negative serum, erythrocytes and antigens were also included as a control. 
The highest dilution of serum causing complete inhibition was considered the endpoint. The 
geometric mean titer was expressed as reciprocal Log2 values of the highest dilution ihat 
displayed HI. 
Experimental design. At two weeks of age all m ovo CY-treated and CY non-treated 
birds were bled and the MTT blastogenesis microassay were performed using B- and T-cell 
mitogens. Statistical analysis using a t-test was performed to select those birds that had 
significant T-cell response and no significant B-cell response. At 3 weeks of age CY-treated 
birds that had significant Con A (T-cell) response and no significant LPS (B-cell) response 
were divided into two groups. The birds in group 1 were each vaccinated subcutaneously 
(SC) with approximately 40 |ig/birds with UV inactivated NDV (CY-NDV). The birds in 
group 2 served as unvaccinated control birds and were injected with PBS (CY-PBS). 
Similarly, the CY-untreated birds that were con A (T-cell) and LPS (B-cell) responsive were 
divided into two groups (group 3 and 4). Group 3 v\?as vaccinated subcutaneously with 
approxirhately 40 |ig/bird of UV inactivated NDV (C-NDV). The birds in group 4 were 
injected with PBS (C-PBS) and served as untreated, unvaccinated controls. The chickens 
were boostered at 5 weeks of age and blood samples were collected weekly. The MTT 
blastogenesis microassay and flow cytometric analysis were performed 1 week after 
vaccination and one week following the booster. The samples used for flow cytometric 
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analysis were pooled samples from 4 chickens within each group. The antibody response to 
NDV for each bird was evaluated weekly by using HI. 
Two trials were conducted. In the first trial, 10 birds (CY-NDV) were used from first 
group and 5 chickens from groups 2, 3, and 4. In the second trial, 12 chickens were used per 
group. 
Statistical evaluation. To study the mitogenic response of each bird to B- and T-cell 
mitogens, analysis of variance (ANOVA) and t-tests were performed. A comparison was 
made between the absorbencies from 4 wells of cultured lymphocytes response vathout 
mitogen and the absorbencies from 4 wells of cultured lymphocytes responding to each 
mitogen (LPS, Con A) for each bird. Differences were determined as highly significant 
(P<0.01), significant (P<0.05), or not significant (P>0.05). The average body weight in the 
CY-treated group was compared with that of the CY-nontreated group using ANOVA. The 
percentage of B-cell and T-cell staining was compared between CY-treated birds and CY-
nontreated birds using ANOVA. 
RESULTS 
Effect of in ovo cyclophosphamide treatment on hatchability, mortality, and 
body weight. Cyclophosphamide treatment in ovo resulted in decreased hatchability and 
increased mortality, as determined at 2 weeks post-hatching (see Table 1). In ovo 
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cyclophosphamide treatment also significantly depressed body weight at 3 weeks of age 
compared to CY-nontreated control birds (see Table 1). 
Whole blood blastogenesis microassay. Figure 1 depicts the responses of PBL of 
one-day-old birds hatched fi^om CY-treated eggs and CY-nontreated eggs to Con A and LPS. 
The results show that reduced responses to both T- and B-cell mitogens were observed in all 
of the CY-treated birds. Significant PBL mitogenic responses in both T- and B-cell mitogens 
were observed in all CY-nontreated birds. Table 2 shows the responses of two-week-old birds 
to Con A and LPS. Approximately 50% of the birds were T-cell positive and B-cell negative 
at two weeks of age. A number of birds that had T-cell responses but not B-cell responses 
were retained in the study for continued monitoring of the B-cell response, whereas those 
birds responding to Con A and LPS were eliminated fi^om the study. 
The blastogenesis results at 4 weeks of age indicated that all birds responded to Con A 
and 1 and 2 CY-treated birds responded to LPS in the 1st and 2nd trial, respectively. At 6 
weeks of age, all the birds continued to respond to Con A and three of the CY-treated birds 
responded to LPS, with a total of 4 of 15 birds responding in the 1st trial. Similarly, in the 2nd 
trial, 2 birds responded to LPS at 4 weeks in addition to the 3 birds responding at 6 weeks, 
giving a total of 5 of 24 birds responding. 
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Table 1. The effect of in ovo cyclophosphamide treatment on hatchability, mortality and body 
weight. 
Trial Treatment Hatchability Mortality^ Body weight^ (gm) 
1 CY^ 106/164 (64%) 13/106 (12.3) ND® 
C® 30/30 (100%) 0/30 (0%) ND 
2 CY 90/144 (62.5%) 5/90 (3.3%) 142.07* 
C 48/50 (96%) 0/48 (0%) 197.400 
^ Birds hatched from eggs injected in ovo with cyclophosphamide. 
® Birds hatched from eggs injected in ovo with PBS. 
^ Cumulative mortality at two weeks of age. 
° Average body weight of group at three weeks of age. 
^ ND = Not done. 
* Statistically significant difference from control group (P < 0.005). 
Antibody response to Newcastle disease vaccine. The results of the NDV 
vaccination are shown in Table 3. Chickens hatched from eggs treated with CY and 
vaccinated with UV-NDV did not produce detectable antibodies during the 1st and 2nd weeks 
post-vaccination. However, 3 birds from the CY-treated group vaccinated with UV-NDV 
developed detectable antibodies during the 1st week post-booster. Antibody titers were 
detected in some of the CY-nontreated birds that were vaccinated with UV-NDV by 2 weeks 
post-vaccination and all produced antibody titers following boosters. 
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Figure 1. Mitogenic response of peripheral blood lymphocytes (PBL) of one-day-old birds 
hatched from CY-treated eggs (A) and CY-nontreated eggs (B) to Con A and LPS. The bar 
represents the average absorbencies from four replicates and the error bars represents the 
standard deviation. A single asterisk (*) denotes a significant difference (P < 0.05) and two 
asterisks (**) denotes a highly significant difference (P < 0.01) in the mitogenic response 
when compared to the control treatment (no Con A or LPS). 
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Table 2. Mitogenic responses of PBL of 2-, 4- and 6-week-oId birds hatched from CY-treated 
eggs and CY-nontreated eggs to ConA and LPS. 
Trial Week No. Treatmenf^ ConA® LPS'^ ConA(+) & LPS(-)° 
2 .92 
10 
CY 
C 
75/89 (84%) 
10/10 (100%) 
36/89 (40%) 
10/10 (100%) 
46/89 (51%) 
0/10 (0%) 
1 
4 15 
10 
CY 
C 
15/15 (100%) 
10/10 (100%) 
1/15 (6%) 
9/10 (90%) 
14/15 (93%) 
1/10 (10%) 
6 15 
10 
CY 
C 
15/15 (100%) 
10/10 (100%) 
4/15 (26%) 
8/10 (80%) 
11/15 (73%) 
2/10 (20%) 
2 85 
36 
CY 
C 
75/85 (88%) 
36/36 (100%) 
27/85 (31%) 
36/36 (100%) 
48/85 (56%) 
0/36 (0%) 
2 
4 24 
24 
CY 
C 
24/24 (100%) 
24/24 (100%) 
2/24 (8%) 
24/24 (100%) 
22/24 (91%) 
0/24 (0%) 
6 24 
24 
CY 
C 
24/24 (100%) 
24/24 (100%) 
5/24 (20%) 
24/24 (100%) 
19/24 (79%) 
0/24 (0%) 
^ CY = cyclophosphamide-treated birds in ovo; C = cyclophosphamide-nontreated birds 
injected with PBS in ovo 
® Number of the birds that had a statistically significant response to Con A (P < 0.05). 
Number of the birds that had a statistically significant response to LPS (P < 0.05). 
° Number of birds that had a statistically significant response to Con A but not to LPS (P< 
0.05). 
Effect of CY on T and B-cell populations in PBL. Table 4 shows the results from 
trial 1 and 2. Data from the ANOVA for flow cytometric analysis are given in the Appendix 
(Tables A1 - A6). In the first trial, the flow cytometric analysis indicated that the percentage 
of lymphocytes expressing CD3 in the CY-treated group was significantly less than CY-
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Table 3. Antibody response to UV-NDV vaccination fi-om CY-treated and CY-nontreated 
birds. 
Trial Treatment"^ Post-vaccination® Post-booster ® 
8 days 14 days 10 days 
CY-NDV 0/10 0/10 3/10 (2.37) 
1 CY-PBS 0/5 0/5 0/5 
C-NDV 0/5 3/5 Of 5/5 (5.4) 
C-PBS 0/5 0/5 0/5 
CY-NDV 0/12 0/12 3/12 (2.6) 
2 CY-PBS 0/12 0/12 0/12 
C-NDV 0/12 4/12 (3) 12/12 (6.2) 
C-PBS 0/12 0/12 0/12 
^ CY-NDV = CY-treated birds vaccinated with NDV; CY-PBS = CY-treated birds injected 
with PBS; C-NDV = CY-nontreated birds vaccinated with NDV; C-PBS = CY-nontreated 
birds injected with PBS. 
® Number of birds having HI titer > 1:2. 
"^Numbers in parentheses indicate, the •geometric mean titer of responding birds to NDV 
expressed as reciprocal Log 2 ' 
nontreated groups. No significant differences were found in the percentage of CD3 positive 
cells in either the CY-treated birds or the CY-untreated birds in the second trial. 
There were sigmficant differences in the percentages of IgM positive cells between 
CY-treated birds and CY-nontreated birds. The staining percentages derived from CY-
nontreated birds were found to be higher than CY-treated birds. 
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Table 4. Effect of in ovo CY treatment on the percentage of B and T lymphocytes from the 
peripheral blood as determined by flow cytometric analysis. 
% Staining'^ 
Trial Week Treatment® Anti-I^'^ Anti- CD3° 
4 CY 1.0* 66.7* 
C 8.2 85.9 
1 
6 CY 1.3* 70 * 
C 17.9 83.2 
4 CY 1.35* 73.1 
C 13.5 78.15 
2 
6 CY 0.8* 85.95 
C 9.5 83.05 
^ Asterisk indicates the value is significantly different from the control group (P < 0.05). 
® CY = cyclophosphamide treated birds; C = cyclophosphamide nontreated birds. 
^ Percentage of staining B-Lymphocjrtes with anti-IgM. 
° Percentage of staining T-Lymphocytes with anti-CDs. 
DISCUSSION 
Cyclophosphamide treatment has been used as a means of abrogating the humoral 
immunity in order to determine the role of T and B cells in protective responses to infectious 
pathogens (9, 12, 13, 15). Cyclophosphamide injected during embryonic development has 
been reported to destroy both B and T lymphocytes. Subsequently, T cells were found to 
regenerate and repopulate lymphoid tissue in the majority of the treated chickens by two 
weeks of age. However, B-cell regeneration remained suppressed for longer periods (7, 14). 
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The results of this study corroborate the eflfect of CY treatment reported in previous 
studies (7, 14). Similar patterns of immunosuppressive effects induced by CY-treatment were 
observed, whereby following hatch a severe lymphoid depletion of B and T cells was evident 
in the PBL of CY-treated birds and functional recovery of T lymphocytes was observed in the 
majority of CY-treated birds by 2 weeks of age. However, the immunosuppressive effect of 
the CY on B cells was not detected in all CY-treated birds and the recovery of antibody 
producing cells may probably have occurred earlier than 2 weeks of age. One of the main 
reasons for the disparity between the studies may have been due to the route of CY injection 
into the eggs. Eskola and Toivanen (7) used intravenous injections of CY at 16 to 18 days of 
embryonic development to ensure a uniform distribution of the drug through the embryo. 
However, injecting CY by this method reduced hatchability, dramatically increased post-hatch 
mortality, and for those few birds that survived, there was a failure to regenerate T cells. 
Lymphocyte responses to PHA and Con A were significantly reduced at 44 days of age which 
may have been due to the severe damage of the epithelial component of the thymus induced by 
the intravenous injection of CY. However, injecting into the allantoic fluid as described in this 
study, was found to be more convenient, time efBcient, applicable for larger quantities of 
eggs, and yielded a substantially lower mortality rate when compared with the intravenous 
method. 
The toxic effect of the CY-treatment on hatchability, mortality, and body weight has 
been reported (1, 6, 7, 14, 15). Schlink et al. (1986) found that high doses of CY 
administration destroyed both the B and T lymphocytes for long periods of time and increased 
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the mortality rate. Low doses of cyclophosphamide, however, reduced mortality but were not 
sufficient to permanently affect the morphology or immmunocompetency of the lymphoid 
organs of the bird (15). Other factors may also influence the immunosuppresive effect of CY 
such as strains of chickens, environmental factors and the origin of CY. These observations 
may emphasize the importance of determining the optimal dose of CY to be used since there 
was a great variability in the resuhs among investigations. 
The flow cytometric analysis indicated that there was a significant reduction of B cells 
in CY-treated birds as compared vwth the CY-nontreated birds. The percentage of anti-IgM 
stained cells in the CY-treated birds were within the background level of the assay. Therefore, 
although there was a low percentage of anti-IgM stained cells, this percentage was within the 
experimental error of the assay and could be indicative of total B-cell ablation. The effect of 
CY treatment on the T cells was also demonstrated in CY-treated groups in the 1st trial. The 
percentage of T cells in CY-treated birds that were identified by CD3 markers were found to 
be approximately 13% less than that of CY-nontreated birds. However, these differences were 
not detected in the 2nd trial in which the percentage of CD3 was not significantly different the 
from control group. The difference between the results in the 1st and 2nd trials might be due 
to the variation among the samples that were analyzed. 
The immunosuppressive effect of the CY treatment on the antibody response to NDV 
was in agreement with the birds' responses to LPS mitogen. Only those birds that had 
significant responses to LPS at six weeks of age developed detectable specific NDV 
antibodies. 
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The fact that a few of the 2-week-old T-cell positive/B-cell negative birds responded 
at 4 and 6 weeks reveals that the immunosuppresive effects of CY on the B-cell system is 
transient and functional recovery of antibody-producing cells could occur at any time, thus 
demonstrating the need for continuous monitoring. This might be achieved by employing a 
technique that would enable mordtoring the humoral immune response in the CY-treated 
birds. In this regard, the suppressive eflfect of CY might be evaluated through flow cytometric 
analysis, blastogenesis response to B-cell mitogens and- specific antibody response to 
pathogens. Those birds that demonstrate a functional and/or morphological recovery of B 
cells should be identified and noted. 
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APPENDIX: DATA AND ANALYSIS 
Table Al. Data from the first trial represent the effect of cyclophosphamide treatment on the 
percentage of T and B lymphocytes in peripheral blood lymphocytes. The values given are 
pooled samples from 4 birds collected at 4 and 6 weeks of age. 
Groups Weeks BCell TCell 
CY 1 63.9 
4 1.2 69.9 
C 8.2 85.7 
ND ND 
CY 2.6 68.4 
6 0 73 
C 23 78 
12.8 90 
Table A2. Analysis of variance for data on the effect of cyclophosphamide treatment on 
percentage of B cells from the first trial. 
Source Degree of Sum of Mean F Pr>F 
Freedom Squares Square Value 
CY 1 310.889 310.887 158.62 0.0504 
Birds 2 6.67 J.J 1.7 0.4767 
Week 1 38.5067 38.50 19.65 0.1413 
CY*Week 1 71.053 71.05 36.25 0.104 
Error 1 1.9600 1.9600 
Corrected total 6 429.0743 
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Table A3. Analysis of variance for data on the eiBfect of cyclophosphamide treatment on the 
percentage of T cells from the first trial. 
Source Degree of Sum of Mean F Pr>F 
Freedom Squares Square Value 
CY 1 431.573 431.573 1726.29 0.0153 
Birds 2 70.2916 35.1458 140.58 0.0595 
Week 1 0.015 0.015 0.06 0.8471 
CY*Week 1 45.63 45.63 182.52 0.047 
Error 1 0.250 0.250 
Corrected total 6 547.76 
Table A4. Data from the second trial represent the effect of cyclophosphamide treatment on 
the percentage of T and B lymphocytes in the peripheral blood lymphocytes. Values given are 
the pooled samples from 4 birds collected at 4 and 6 weeks of age. 
Trial Groups Weeks B Cell T Cell 
CY 0.8 73.1 
4 1.9 73.2 
C 13.9 73.4 
13 82.3 
CY 1.8 89.9 
6 0.2 82.5 
•C 10.3 76.9 
8.8 82.8 
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Table A5. Analysis of variance for data on the effect of cyclophosphamide treatment on 
percentage of B cells from the second trial. 
Source Degree of Sum of Mean F Pr>F 
Freedom Squares Square Value 
CY 1 213.2115 213.2115 222.97 0.0045 
Birds 2 1.5025 0.75125 0.79 0.5600 
Week 1 9.03125 9.03125 9.44 0.0916 
CY*Week 1 6.30125 6.30125 6.59 0.124 
Error 2 1.9125 
Corrected total 7 231.958 
Table A6. Analysis of variance for data on the effect of cyclophosphamide treatment on the 
percentage of T cells from the second trials 
Source Degree of Sum of Mean F Pr>F 
Freedom Squares Square Value 
CY 1 1.361125 1.36125 0.17 0.7225 
Birds 2 68.0825 34.04125 4.17 0.1933 
Week I 113.25125 113.251 13.89 0.0651 
CY*Week 1 61.05125 61.05125 7.49 0.1117 
Error 2 16.3125 8.15625 
Corrected total 7 260.058 
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STUDIES ON NEWCASTLE DISEASE IN CHICKENS: 
THE ROLE OF CELL MEDIATED IMMUNITY IN PROTECTION 
Manuscript for submission to Avian Diseases 
A. D. Maraqa and D. L. Reynolds 
SUMMARY 
The role of cell mediated immunity (CMI) in protection of birds from Newcastle 
disease (ND) was investigated by two different strategies in which only NDV specific CMI 
was conveyed without a humoral response. In the first strategy, selected 3-week-old 
pathogen-fi-ee (SPF) birds were vaccinated with either live Newcastle disease virus (LNDV), 
UV inactivated NDV (UVNDV), SDS treated NDV (SDSNDV), or phosphate buffered saline 
(PBS) (negative control) by the subcutaneous route. Birds were booster vaccinated 2 weeks 
later and challenged with the Texas GB strain of NDV 1 week after the booster. All 
vaccinated birds had specific CMI responses to NDV as measured by a MTT blastogenesis 
microassay. Specific antibody response was detected in birds vaccinated with LNDV and 
UVNDV. However, birds vaccinated with SDSNDV developed antibodies which were 
detected by the Western blot analysis but not by the HI test or VN test. Protection from 
challenge was only observed in those birds which had NDV specific antibody response. That 
is, birds with demonstrable CMI and a specific antibody response were protected, whereas 
birds with demonstrable CMI but no specific antibody response were not protected. In the 
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second strategy, birds jfrom SPF embryos were treated in ovo with cyclophosphamide (CY) to 
deplete B cells. At 2 weeks of age, the birds were monitored and selected for the presence of 
T-cell activity and the absence of B-cell activity. Birds that had a significant T-cell response 
but not a B-cell response were vaccinated with either LNDV, UVNDV or PBS at 3 weeks of 
age along with the CY-untreated control birds. The birds were booster vaccinated at 5 weeks 
of age and were challenged with the Texas GB strain of NDV at 6 weeks of age. All birds 
vaccinated with LNDV or UVNDV had a specific CMI response to NDV. Specific NDV 
antibodies were detected in all CY-nontreated vaccinated birds and some of the CY-treated 
vaccinated birds that were found to have regenerated their B-cell function at one week post-
booster. The challenge results clearly revealed that CY-treated birds that had specific CMI 
and antibody responses to LNDV or UVNDV were protected as were the CY-nontreated 
vaccinated birds. However, birds that had an NDV-specific CMI response but did not have 
NDV-specific antibodies were not protected firom challenge. The results from both strategies 
indicate that specific CMI to NDV by itself is not protective against virulent NDV challenge. 
The presence of specific antibodies is important in providing protection fi-om Newcastle 
disease. 
Keywords: cyclophosphamide, Newcastle disease virus, cell mediated immune 
response. 
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Abbreviations: 
B bursa-dependent lymphocytes 
CMF-PBS calcium and magnesium free-phosphate buffered saline 
CMI cell-mediated immunity 
Con A concanavalin A 
EIDjo embryo infectious dose of 50 percent 
HI hemagglutination inhibition 
IBD infectious bursal disease virus 
LNDV live Newcastle disease virus. 
LPS lipopolysaccharide 
MTT 3-[4,5-Dimethythia2ole-2-yl],2-5-diphenyltetrazolium bromide) 
NDV Newcastle disease virus 
PBL peripheral blood lymphocjrtes 
PBS phosphate-buffered saline 
SDS sodium dodecyl sulfate 
SV5 Simian virus 5 
SI stimulation index 
SPF specific pathogen firee 
VN virus neutralization 
UVNDV ultraviolet inactivated Newcastle disease virus 
T Thymus-dependent lymphocytes 
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INTRODUCTION 
Newcastle Disease (ND) is an economically important viral disease of poultry and is of 
major concern worldwide (2). It occurs in a variety of avian species and may cause respiratory 
distress, diarrhea, cessation of egg production, nervous signs, depression and high morbidity 
and monality if not controlled (2). The severity of the disease produced by a virulent strain of 
NDV has been found to be greatly influenced by the immune status of the host. It was 
reported that the level of immunity against ND determines the severity of the disease (5). 
Both cellular and humoral immune responses have been suggested to play important 
roles in the host's defense against NDV infection (6, 10, 11, 16, 18, 20). Antibodies directed 
against surface glycoproteins of NDV have been reported to inactivate or neutralize the free 
virus. These antibodies inhibit virus attachment to the cell host receptors and prevent the 
spread of the virus from cell to cell (18). The antibody response to NDV occurs rapidly with 
detectable neutraliang antibodies, usually detected in the serum of birds within 4 to 6 days 
following vaccination with live attenuated vaccines (2). 
Cell mediated immunity (CMI) has been suggested to be an important factor in the 
development of protection in chickens vaccinated against ND (6, 10, 16, 18, 20). Cell 
mediated immunity has been reported as the first immunological response being detected as 
early as 2 to 3 days following ND vaccination (10). It has been shown that early protection 
following vaccination can be demonstrated in the presence of low levels of antibodies or in the 
absence of detectable antibodies (11). Furthermore, recent studies with other paramyxoviruses 
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have demonstrated that protective immunity is mediated by CMI whereas serum neutralizing 
antibodies have been found to play a minor role in protection (23). While there have been 
suggestions of a protective role for cellular immunity, a definitive relationship between 
protection and the cellular immune response has not been determined in the absence of a 
detectable antibody response (16, 20). 
The objective of this study was to ascertain whether cell mediated immunity is a key 
component in the protection of chickens against Newcastle disease. Two strategies were used 
to achieve this objective. The first strategy was to destroy neutralizing epitopes on the virus 
by treating NDV with a denaturing agent such as SDS. By this method, NDV-specific 
neutralizing antibody was not induced, but NDV specific CMI was induced in 
immunocompetent birds. The second strategy was to deplete the humoral immune response of 
the bird while retaining the T-cell response and use intact NDV as an immunogen. This was 
achieved by chicken embryo in ovo treatment with cyclosphosphamide (CY) from specific 
pathogen-firee (SPF) chickens eggs (9). 
MATERIALS AND METHODS 
Eggs. Specific pathogen-free (SPF) white leghorn eggs were purchased (Hy-Vac Co., 
Gowrie, lA). The chickens were hatched and housed in a facility designed for maintaining SPF 
status. 
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Medium and reagents. Cyclophosphamide (CY) (Cytoxan, Mead Johnson & 
Company, Evansville, Indiana) was obtained in a dry form containing active ingredients. An 
aqueous solution was prepared by reconstituting 2 grams in 100 ml (20 mg/ml) of calcium and 
magnesium-free phosphate-buffered saline (CMF-PBS) and filtered through a 0.22 jim syringe 
filter. 
A solution ofRPMI 1640 supplemented with 25 mM HEPES and L Glutamine (Sigma 
Chemical Co., St. Louis, MO), penicillin (200 ng/ml), and streptomycin (200 |ig/ml) was used 
for washing and resuspending the cells, diluting the mitogens and antigen, and culturing the 
cells. Concanavalin A (Con A; Sigma Chemical Co., St Louis, MO) was used as the T-cell 
mitogen. An aqueous solution was prepared by dissolving 100 mg in 10 ml of CMF-PBS and 
filtering it through a 0.22 [im syringe filter. Con A was used at a working concentration of 50 
}j,g/ ml for whole blood and at a concentration of 6 |ig/ml for purified lymphocytes. 
Lipopolysaccharide (LPS) from Salmonella typhimurium (Sigma Chemical Co., St. Louis, 
MO) was used as the B-cell nutogen. It was prepared in CMF-PBS as 1 |ig/|il. All stock 
solutions were dispensed into small aliquots and stored at -20 C until used. LPS was used at a 
working concentration of 1 [ig/ml for the whole blood blastogenesis microassay. A solution of 
MTT (3-[4,5-DimethyIthiazoIe-2-yI],2-5-diphenyltetrazolium bromide; Sigma Chemical Co, 
St. Louis, MO) was prepared by dissolving 10 mg of MTT in 1 ml of CMF-PBS and 
solubilized by sonication. The solution was then filtered through a 0.45 pim syringe filter and 
stored at 4 C in a dark bottle. The HCl-isopropanol (0.04 N HCl-isopropanol) solution was 
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prepared by adding 40 ml of 1 N HCl to one liter of isopropanol. The HCl-isopropanol was 
stored at room temperature in a light-proof bottle. 
Virus propagation and purification. Newcastle disease virus purification was based 
on the method of Alexander and Collins (4). The lentcgenic strain Bl, Bl of NDV, was 
propagated in 9-day-old embryonated SPF chicken eggs. The embryonated eggs were 
inoculated by the chorioallantoic route and incubated for 5 days at 37 C. The allantoic fluid 
was clarified by centrifiigation at 3000 x g for 30 minutes. The virus was pelleted by 
centrifiigation at 50,000 x g for 2 hours. The pellet was resuspended in 0.0IM Tris-NaCl pH 
7.2 and applied to a discontinuous sucrose gradient made from 14 ml 50% w/v and 21 ml 20% 
w/v in 10 mM Tris, O.lMNaCl, ImM EDTA, pH 7.4. Following centrifijgation for 2 hours at 
50,000 X g, a visible band was observed at the sucrose gradient interface. The virus band was 
collected and pelleted at 50,000 x g for 2 hours. Then the pellet was resuspended in PBS. The 
purified virus was assayed for total protein concentration by Bio-Rad assay (Bio-Rad 
Laboratories, Hercules, CA) and the purity was assessed by Coomassie blue-stained 
polyacrylamide gel electrophoresis. The purified virus was inactivated by exposure to 
ultraviolet light for 40 minutes and tested for virus replication in the embryonic eggs. A 
concentration of 0.3 |Ag/ml of ultraviolet light inactivated NDV (UVNDV) was used for 
measuring cell mediated immunity in the blastogenesis micro-assay and 40 jig/bird for 
vaccination. The purified NDV was treated with an equal volume of 4% SDS and heated at 
100 C for two minutes. The SDS-treated NDV was mixed with incomplete Freund's adjuvant 
and used for vaccination. 
59 
The velogenic Texas GB strain of NDV was propagated in embryonic eggs and used 
for challenge at 10"ELD5o/birds. 
Preparation of purified lymphocytes. Three milliliters of blood were collected from 
each chicken by venipuncture in a syringe containing 20 units/ml of herpin. The blood was 
diluted 1:1 with anKPMI 1640 medium. The blood was layered on Lymphoprep™ (Accurate 
Chemical & Scientific Corporation, Westbury, NY) and centrifiiged at 800 x g for 15 minutes 
at room temperature. The cellular band at the medium/Lymphoprep™ interface was collected 
and washed twice with RPMI 1640 medium. The viable lymphocytes were counted by trypan 
blue dye exclusion after the addition of a 10 fil solution of trypan blue in 90 |il of 
physiological saline (0.15 M NaCl). After the cell concentration was adjusted to 5 x 10® 
lymphocytes/ml in RPMI 1640, the purified lymphocytes were used for measuring CMI to 
NDV. 
Cyclophosphamide treatment. The procedure for CY injection was performed 
similarly to that previously described (15). Briefly, eggs were injected with CY during day 16, 
17 and 18 of embryonic development. This was done by candling the eggs to identify the air 
sac of the embryo. After the area of the shell above the air sac was disinfected with a 3% 
tincture of iodine, a drill was used to make a small hole in the eggshell, and an aqueous 
solution of CY (0.1 ml, 20 mg/ml) was injected into the air cell membrane by insertion into the 
hole with a 25-gauge 5/8-inch (16 mm) needle attached to a syringe. Then the hole was sealed 
with transparent tape and the eggs were returned to the incubator. The same procedure was 
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used to inject the control eggs with CMF-PBS at day 16 of embryonic development and on 
the two succeeding days. 
Colorimetric blastogenesis assay. The procedure for the blastogenesis microassay 
was performed similarly to the procedures previously described (17). Briefly, the assay was 
carried out in a 96-well flat-bottomed tissue culture plate (Coming Laboratory Sciences Co., 
Coming, NY). Two hundred microliters of RPMI containing Con A 6 |ig/ml or 0.3 ^g/ml 
UV-NDV or media without antigen (control well) were dispensed in each well and 10 (il of 
purified lymphocytes were added to each well. The plate was incubated at 37 C for 93 hours, 
in a humid atmosphere of 5%C02 At 93 hours of incubation period, 20 |il of MTT (10 
mg/ml) were added in each well and the plate was reincubated for 3 hours. At 96 hours of 
incubation the plate was centrifuged at 1000 x g for 10 minutes at room temperature. The 
supematant was removed carefully and 175 nl of IN HCl-isopropanol were added into each 
well to dissolve the formazan crystals. Then the plate was shaken for 20 minutes on a plate 
shaker (mini-orbital shaker, Bellco Biotechnology, Vineland, NJ) and the blood lymphocytes 
were thoroughly resuspended by multiple pipettings with a micropipetter. The plate was 
centrifijged at 1000 x g for 10 minutes. One hundred microliters of supematant were 
transferred to the corresponding wells of a new 96-well plate. The absorbance of each well 
was measured by a microtiter ELISA reader (Model EL310, BIO-TEK Instmments, Inc., 
Winooski, VT 05404) at a wavelength of 550 nm. The response was reported as a stimulation 
index (SI) as calculated by the following formula; 
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(mean absorbance of stimulated culture) - {mean absorbance of unstimulated culture) 
S I  ~  — — — — — — — — — — — — — — — — —  (mean absorbance of unstimulated culture) 
Western blot. Purified NDV was solubilized in a gel sample buffer containing 0.0625 
M Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 0.001% bromophenol blue and heated at 100 C 
for 2 minutes. The proteins were separated on a 10% polyacrylamide gel according to the 
Laemmli procedure (14) and the gel was electrophoresed at a constant voltage of 150 V for 4 
hours. Part of the gel was stained with Cdomassie brilliant blue G 250 (Pharmacia Biotech, 
Piscataway, NJ) destained with methanol and fixed. The remaining portion of the gel was 
prepared for transfer onto a 0.45 pm nitrocellulose membrane (Trans-Blot Transfer Medium, 
Bio-Rad Laboratories, Hercules, CA) for a Western blot analysis. The transfer was carried out 
for 4 hours in a transfer buffer consisting of 25 mM Tris, 192 mM Glycine (pH 8.3) and 20% 
v/v methanol at a constant voltage of 60 V. After transfer the membrane was stained with 
0.05% Ponceau S dye (Fisher Biotech, Fisher Scientific, Fair Lawn, NJ) in a 1% acetic acid 
solution for band visualization. The nitrocellulose membrane containing the separated proteins 
was cut into 7 mm strips and each strip was placed into individual wells in an immunoblotting 
plate. An avidin-biotin immunobinding assay was used for developing the blot as previously 
described (7). Briefly, a nitrocellulose membrane containing the separated proteins was 
blocked vwth 3% skim milk in TBS (500 mM NaCl, 20 mM Tris, pH 7.5) for 1 hour. 
Antiserum was diluted 1:400 in TBS containing 0.3% skim milk and added to each strip. After 
one hour of incubation, secondary biotinylated antibodies (biotinylated anti-chicken IgG, 
vector Laboratories, Burlingame, CA) at a dilution of 1:5000, strept-avidin at a dilution of 
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1:2000 and the chromogen (4-chloro-l-Naphthol; Sigma chemical Co., St. Louis, MO) were 
subsequently added. Washing and blocking the nitrocellulose membrane were performed 
between each step. Then the immunoblotting plate was incubated in the dark until a color 
reaction developed against the white (nitrocellulose) background, and the reaction was 
stopped by washing with TBS. 
Sample collection for virus isolation. Cotton-tipped applicators were used for 
swabbing the trachea. Following tracheal swabbing, each cotton applicator was placed into 2 
ml of tryptose phosphate broth containing penicillin and streptomycin and then frozen (-70 C). 
On the day of egg inoculation, the tubes were thawed and the swabs were removed. The 
remaining fluid was centrifuged at 1000 x g for 10 minutes and the supernatant was collected 
for embryo inoculation. Five 9-day-old embryonated eggs for each tracheal swab sample were 
inoculated via the chorioallantoic sac with 0.1 ml per embryo. Then the eggs were incubated 
at 37 C for 7 days. The presence of NDV was detected by hemagglutination (HA) using 1% 
turkey erythroc5rtes. 
Hemagglutination inhibition (HI) test. The HI test was performed as described (3). 
Briefly, twofold serial dilutions of serum were made in a 96 well, round-bottom microtiter 
plate containing 50 |il of PBS in the first row and 50 |j,I of NDV antigen (10 HA units) in the 
remaining 11 rows. Serum dilutions ranged fi-om 1:2 to 1:2048. The antigen serum mixture 
was incubated for 30 minutes at 37 C. Then, 50 |j,l of a 0.05% turkey erythrocyte suspension 
were added to each well and reincubated for 30 minutes. A positive serum, a negative serum, 
erythrocytes and antigens were also included as controls. The highest dilution of serum 
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causing complete inhibition was considered the endpoint. The geometric mean titer was 
expressed as reciprocal Logi values of the highest dilution that displayed HI. 
Virus neutralization (VN) test. The virus neutralizion test was performed as 
described (3), except the ST cell line was used instead of chicken embryo fibroblasts. Briefly, 
50 microliters of media were added into an empty 96-well flat-bottomed tissue culture plate 
(Coming Laboratory Sciences Co., Coming, NY). Another 50 |j,l of the semm sample were 
added into the first column. Twofold serial dilutions were made across the plate to achieve 
dilutions fi-om 1:2 to 1:1024. One hundred tissue-culture infectious doses (TCIDso) of the 
Texas GB strain of NDV in 50 |j1 were mixed with equal volumes of the serum dilutions. Then 
the plate was incubated for one hour at 37 C in a humidified 5% CO2 incubator. Fifty |il of 
media without antibodies were mixed with the virus suspension for the vims control, and 100 
|al of medium without antibodies or vims were used for a cell control. Positive and negative 
semm controls were also included in the experiment. All samples were tested in quadmplicate. 
Following a 1-hour mcubation period, 100 ^1 of the vims-semm mixture were transferred into 
96-well culture plates containing monolayers of a swine testicular (ST) cell line and incubated 
at 37 C for 72 hours. The plate was examined for cytopathic effect (CPE) to confirm the 
presence of the vims. The 50% neutralizing endpoint (EDso) was calculated by the method of 
Reed and Muench (21). 
Experimental design. In the first experiment, 4 groups of 3-week-old SPF chickens 
were injected subcutaneously with approximately 40 ^ig^ird of either LNDV, UVNDV, SDS-
treated NDV or PBS. The birds were booster vaccinated at 5 weeks of age. Blood samples 
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were collected weekly for an evaluation of cellular and humoral immune response. The birds 
were challenged 1 week following booster vaccinations with 10^ EID50 of Texas GB strain 
NDV which was administered intramuscularly. The birds were observed for 2 weeks following 
challenge. Tracheal swabs were taken at 4 days post-inoculation and used for virus isolation. 
Two trials were conducted, with 12 birds per group used in the 1st trial and 10 birds per 
group in the 2nd trial. 
Birds hatched from SPF w ovo CY-treated and CY-nontreated eggs were used in the 
second experiment. At 2 weeks of age, blood samples were taken from all in ovo CY-treated 
and CY-nontreated birds and the MTT blastogenesis microassay was performed using B- and 
T-cell mitogens. Statistical analysis were performed using t-tests to select those birds that had 
a significant T-cell response and no significant B cell response. At 3 weeks of age CY-treated 
birds that had a significant Con A (T-cell) response and no significant LPS (B cell) response 
were vaccinated subcutaneously (SC) with approximately 40 |J,g^ird, with either LNDV, 
UVNDV or injected with PBS. Similarly, the CY-untreated birds that were Con A (T cell) and 
LPS (B ceU) responsive were vaccinated subcutaneously with 40 ^ig^irds with either LNDV, 
UVNDV or PBS. The chicks were booste'red at 5 weeks of age and blood samples were 
collected weekly for evaluation of cellular and humoral immune response. Challenge testing 
was administered intramuscularly one week post-booster with 10^ EHDso of the Texas GB 
strain of NDV per bird, and the chicks were observed for 2 weeks afterward. Tracheal swabs 
were taken 4 days post-inoculation and used for virus isolation. 
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Two trials were conducted. In the 1st trial 10 CY-treated chickens were vaccinated 
with UVNDV and 5 were used for other groups. Birds vaccinated with LNDV were not 
included in the 1st trial. In the 2nd trial, 12 birds were used per group. 
Statistical evaluation. T-tests were conducted to test the mitogenic response of each 
CY-treated bird and CY-nontreated bird to ConA and LPS mitogens. Stimulation index (SI) 
values were used for statistical evaluation of cell-mediated immune response. The SAS 
statistical software (SAS Institute, Inc., Cai7, NC) was used to compare the average SI of 4 
birds from each group vaccinated with NDV vaccine and those from unvaccinated groups. 
Duncan's multiple range test was used to determine the differences in CMI among vaccinated 
and control groups, and statistical significance was expressed as highly significant (P < 0.01), 
significant (P < 0.05), or not significant (P > 0.05). Correlations between HI, CMI and 
protection for the two experiments were determined by linear regression analysis and 
expressed as a correlation coefficient (r) for which r > 0 indicated a positive linear relationship 
and r < 0 indicated a negative relationship. 
RESULTS 
Humoral immune response. The results from trials 1 and 2 of experiment 1 are 
shown in Table 1. The results revealed that chickens vaccinated with LNDV and UVNDV 
produced detectable antibody titers as measured by the HI test, with antibody titers increasing 
subsequent to booster. However, chickens vaccinated with SDS treated NDV did not produce 
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Table 1. Antibody titers to NDV as measured by the hemagglutination inhibition (HE) and 
virus neutralization (VN) assays of birds vaccinated with live, UV inactivated or SDS-treated 
NDV preparations. 
HI titers® VN titers® 
Trial Treatment"^ Post-vaccination Post-booster Post-booster 
lOdays 14 days 10 days 10 days 
LNDV 4.4 (3-6f 6.1(6-7) 9.2 (9-10) 9.62 
UVNDV 0 3 (0-4) 6.2 (5-8) 6.02 
1 SDSNDV 0 0 0 <2 
C-PBS 0 0 0 <2 
LNDV 5 (5-6) 7.3 (6-9) 9.5 (9-10) 9.5 
UVNDV 0 2.8 (2-5) 5.2 (5-7) 5.5 
2 SDSNDV 0 0 0 <2 
C-PBS 0 0 0 <2 
^ LNDV = Live NDV; UVNDV = UV inactivated NDV; SDSNDV = SDS treated NDV; C-
PBS = PBS control. 
® Geometric mean titers of responding birds expressed as reciprocal Log2. 
^ Numbers within parentheses indicate the range of HI titers within the group. 
detectable levels of specific antibody to NDV as measured by the HI assay. Similarly, the virus 
neutralization results shown in Table 1 revealed that virus neutralizing antibodies were 
detected in all the chickens inoculated with LNDV and UVNDV but not in chickens 
vaccinated with SDSNDV or uninoculated control. 
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Western blot tests revealed that birds vaccinated with LNDV, UVNDV and SDSNDV 
had positive sera that reacted with NDV polypeptides. However, not all birds vaccinated with 
NDV treated with SDS had the same reaction to all the NDV polypeptides (Figure 1). 
Table 2 shows the HI titers of sera from trials 1 and 2 of experiment 2. The resuhs 
revealed that in ovo CY-treated birds that were vaccinated with UVNDV did not produce 
detectable antibody titers during the first and second weeks post-vaccination. However, 
antibody titers were detected in 3 birds at one week post-booster, and in all CY- nontreated 
birds that were vaccinated with LNDV and some of the birds vaccinated with UVNDV by 2 
weeks post-vaccination. In addition, antibody titers increased in all NDV vaccinated, CY-
nontreated birds subsequent to booster vaccinations. 
The virus neutralization results (Table 2) also showed that all CY-treated vaccinated 
birds, with the exception of those birds that responsed to the HI test, had no serum antibody 
response. However, a substantial response was detected in the CY-nontreated vaccinated 
birds. 
Blastogenesis response. The resuhs from the blastogenesis microassays that were 
performed on the samples of four birds from each group are displayed in Tables 3 and 4. The 
statistical analysis of the CM responses is shown in the Appendix (Table A7-A10). The 
resuhs of the first experiment revealed that those birds vaccinated with LNDV, UVNDV and 
SDSNDV had a significant CMI response to NDV as compared with the control groups 
(Table 3). There were no significant differences between blood lymphocyte responses isolated 
from the three inoculation groups. Control birds did not produce a specific response to NDV. 
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SDS-treated 
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Table 2. Antibody response of CY-treated and CY-nontreated birds vaccinated with live or 
UV inactivated NDV. 
HI titers VN titers 
Trial Treatment^ Post-vaccmation® Post-booster® Post-booster^ 
8 days 14 days 10 days 10 days 
CY-UVNDV 0/10 0/10 3/10 (2.67)° 2.3 
1 CY-PBS 0/5 0/5 0/5 <2 
C-UVNDV 0/5 3/5 (3) 5/5 (5.4) 5.6 
C-PBS 0/5 0/5 0/5 <2 
CY-LNDV 0/12 0/12 3/12 (3.6) 2.3 
CY-UVNDV 0/12 0/12 3/12 (2.6) 3.1 
2 CY-PBS 0/12 0/12 0/12 <2 
C-LNDV 12/12 12/12 (6.1) 12/12 (9.2) 9.62 
C-UVNDV 0/12 4/12 (3) 12/12 (6.2) 6.02 
C-PBS 0/12 0/12 0/12 <2 
^ CY-LNDV = CY-treated birds vaccinated with LNDV; CY-UVNDV = CY-treated birds 
vaccinated with UVNDV; CY-PBS = CY-treated birds injected with PBS; C-NDV = 
control birds vaccinated with LNDV; C-UVNDV = control birds vaccinated with UVNDV; 
C-PBS: CY-control birds injected with PBS. 
® Number of birds having HI titers > 1:2. 
^ Geometric mean titer of responding birds expressed as reciprocal Loga. 
° Numbers in parentheses indicate the geometric mean titer of responding birds expressed as 
reciprocal Log2. 
The results of the second experiment revealed that the birds vaccinated with UVNDV 
or LNDV had specific CMI responses to NDV that were significantly higher than that of the 
PBS injected birds (Table 4). 
Challenge results. Tables 5 and 6 show the challenge results from the first and second 
experiments. The results revealed that the birds which did not produce a specific antibody 
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Table 3. Lymphocyte blastogenesis results from birds vaccinated with live, UV inactivated or 
SDS-treated NDV preparations. 
Trial Treatment^ Mean SI® ± standard deviation 
LNDV 0.640' ± 0.233* 
1 UVNDV 0.5746'±0.153 
SDSNDV 0.436" ± 0.052 
C-PBS 0.07''+ 0.195 
LNDV 0.7151'±0.443 
2 UVNDV 0.250'± 0.156 
SDSNDV 0.4575' ± 0.059 
C-PBS 0.043*' ± 0.052 
^ LNDV = birds vaccinated with live NDV; UVNDV = birds vaccinated with UVNDV; 
SDSNDV = birds vaccinated with SDS treated NDV; C-PBS = control birds injected with 
PBS 
® Average stimulation index of four birds. 
* Values within the same colunm and having different superscripts are significantly different 
(P<0.05) as measured by Duncan's multiple range test. 
response to ND developed clinical signs of NDV and died by three or four days post-
challenge. Due to mortality, tracheal swab samples could not be taken from birds that 
perished. The LNDV and UVNDV groups did not develop clinical signs of ND nor were 
viruses demonstrated from their tracheal swabs. 
Statistical analyses using correlation coefficients from the two experiments are given in 
the Appendix (Table A1-A6). The results indicated that there was a high correlation between 
the presence of a specific antibody response as measured by HI and protection (0.91), whereas 
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Table 4. Lymphocyte blastogenesis test results from CY-treated and CY-nontreated birds 
vaccinated with live or UV inactivated NDV preparations. 
Trial Treatment^ Mean SI® ± standard deviation 
CY-UVNDV 0.5217''± 0.0519* 
1 CY-PBS 0.0325''±0.0178 
C-UVNDV 0.7772"! 0.442 
C-PBS 0.045''±0.032 
CY-LNDV 0.61 ©"±0.108 
CY-UVNDV 0.77805" ±0.173 
2 CY-PBS 0.0645''±0.142 
C-LNDV 0.640"+ 0.233 
C-UVNDV 0.575 "±0.1539 
C-PBS 0.070 •'±0.195 
^ CY-LNDV = CY-treated birds vaccinated with live NDV; CY-UVNDV = CY-treated birds 
vaccinated with UVNDV; CY-PBS = CY-treated birds injected with PBS; C-LNDV = 
control birds vaccinated with live NDV; C-UVNDV = control birds vaccinated with 
UVNDV; C-PBS = control birds injected with PBS 
® Average stimulation index of four birds. 
* Values in the same column having different superscripts are significantly different (P<0.05) 
as measured by Duncan's multiple range test. 
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Table 5. Challenge test results of chickens vaccinated with live, UV inactivated or SDS 
treated NDV after challenge with the Texas GB isolate of NDV. 
Trial Group No.° Mortality'^ Virus shedding^ 
LNDV 12 0/12 Neg. 
1 UVNDV 12 0/12 Neg. 
SDS-NDV 12 12/12 ND 
C-PBS 12 12/12 ND 
LNDV 10 0/10 Neg. 
2 UVNDV 10 0/10 Neg. 
SDS-NDV 10 10/10 ND 
C-PBS 10 10/10 ND 
^ LNDV = birds vaccinated with live NDV; UVNDV = birds vaccinated with UV-NDV; 
SDSNDV = birds vaccinated SDS treated NDV; C-PBS = control birds injected with PBS 
® Number of the birds in each group. 
^ Number of dead birds from total challenged birds. 
^ Neg. = No virus shedding; ND = Not done. 
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Table 6. Challenge test results of CY-treated and CY-nontreated birds vaccinated with LNDV 
or UVNDV. Birds were challenged with the Texas GB strains of NDV. 
Trial Group ^ No.® Mortality'^ Virus shedding'^ 
CY-UVNDV 10 7/10 0/3 
1 CY-PBS 5 5/5 ND 
C-UVNDV 5 0/5 Neg 
C-PBS 5 5/5 ND 
CY-LNDV 12 9/12 0/3 
CY-UVNDV 12 9/12 0/3 
2 CY-PBS 12 12/12 ND 
C-LNDV 12 0/12 Neg. 
C-UVNDV 12 0/12 Neg. 
C-PBS 12 12/12 ND 
CY-LNDV = CY-treated birds vaccinated with live NDV; CY-UVNDV = CY-treated birds 
vaccinated with UVNDV; CY-PBS = CY-treated birds injected with PBS; C-LNDV = 
control birds vaccinated with LNDV; C-UVNDV = control birds vaccinated with UVNDV; 
C-PBS = control birds injected with PBS 
® Number of the birds in each group. 
^ Number of dead birds from total challenged birds. 
° Neg. = No virus shedding; ND = Not done 
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an intermediate correlation was found between the presence of specific CMI to NDV and 
protection (0.47). 
DISCUSSION 
Two approaches have been commonly used for identifying the specific components of 
the immune system involved in protection (20, 23). One approach has been to destroy one 
component of the immune system and then demonstrate the protective immunity of the other 
component (16, 20, 23). Another approach is to passively transfer immunity firom an immune 
donor to a nonimmune animal recipient (23). Cyclophosphamide was used in this study as an 
immunosuppressive agent to deplete B lymphocytes and suppress humoral immunity (9). In 
addition, immune-competent birds were vaccinated with denatured NDV proteins to elicit a 
specific CMI response without inducing a specific HI or neutralizing activity. The results of 
this study indicated that there was a high positive correlation between the presence of specific 
NDV antibodies and protection jfrom virulent NDV challenge. The presence of an NDV-
specific CMI response in the absence of NDV specific antibodies did not protect birds against 
virulent NDV challenge. Cyclophosphamide-treated birds that were vaccinated with LNDV or 
UVNDV at three weeks of age and developed a specific CMI response did not produce 
specific antibodies and were susceptible to virus challenge. It should be noted that a small 
number of CY-treated birds that survived the virus challenge had developed an antibody 
response to NDV one week post-booster. The antibody titers to NDV in the CY-treated birds 
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that were protected was found to be low as measured by the HI test. It has been reported that 
protection can be demonstrated in the presence of very low levels of antibodies (5). Gough 
and Alexander (11) found 100% protection in chickens with low antibody titers (from less 
than 1:2 to 1:32) as measured by HI. 
The results of this study also demonstrated the importance of the protective epitopes 
that induce specific antibody response to NDV in protection. All sera from chickens 
immunized with SDS-treated NDV had antibodies that were detected by the Western blot 
analysis but not with the HI test or VN test. Those birds not having NDV-specific HI or VN 
antibodies were not protected from challenge. It was hypothesized that SDS treatment of the 
virus may have destroyed the conformational epitopes needed for inducing virus-neutralizing 
activity. This resuh has also been reported to occur with other viruses. For example, 
immunizing chickens with denatured proteins of IBDV rendered the birds incapable of 
inducing virus-neutralizing antibodies (13). 
A lymphocyte blastogenesis microassay was used in this study to measure cell 
mediated immunity. It was evident in the experiments that CMI was induced when the 
chickens were vaccinated with ND vaccine. All birds, including the CY-treated and CY-
nontreated birds that were vaccinated with UVNDV, LNDV or SDSNDV, elicited specific 
CMI as measured by the MTT blastogenesis microassay. No statistical differences were 
observed among any of the vaccinated groups. The results of the blastogenesis assays in the 
present study support the conclusions of previous studies (12, 10). Ghumman and Bankowski 
(10) found that birds vaccinated with LNDV or inactivated ND vaccine elicited CMI as early 
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as the second day following vaccination. Denatured protein was found to be capable of 
inducing mitogenic responses of PBLs from cattle immunized with bovine herpes virus 1 
(BHV-1) as detected in the lymphocyte proliferation assay (12). 
The quantity of NOV antigens that was used in the in vitro blastogenesis microasssay 
was less than that reportedly used in other studies (10, 16). Preliminaiy studies performed in 
our laboratory indicated that using a low concentration (0.3-0.6 jag/ml) of purified UVNDV 
produced a specific response without producing a nonspecific response, thus averting the need 
to eliminate any nonspecific reactivity when using NOV with the blastogenesis microassay as 
an indicator for NOV specific CMI (22). 
One interpretation from the results of this study (see above) is that antibodies are key 
components for protective inununity to M). This interpretation might be considered 
contradictory to other reports that have emphasized the importance of cell mediated immunity 
as a key component in protection (10, 11, 16, 20). For example, Marino and Hanson (16) 
reported that in ovo bursectomized birds vaccinated with NOV were protected against virus 
challenge. While their findings suggested a protective role for cellular immunity, they may 
have overlooked the importance of antibody-mediated protection. In their study, vaccinated 
bursecton^ed birds also developed antibodies, but at much lower titers than control non-
bursectomized vaccinated birds. The low titer in bursectomized birds was found to be 
significantly lower and assumed to be non-protective. Therefore, protection was attributed to 
CMI. 
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The importance of humoral immunity as a key component of protection against ND is 
supported by studies involving infectious bursal disease virus (EBDV). It was shown that 
infection with IBD at one day of age causes a reduction in serological response to ND 
vaccination, thereby prolonging virus excretion and increasing the susceptibility and severity 
of ND (1, 19). 
Several research findings have supported the importance of CMI in controlling other 
paramyxovirus infections. Young et al. (23) found that the immune response to Simian virus 5 
(SV5) was interposed entirely by cell mediated immunity and serum-neutralizing antibodies 
which played only a minor role in protection. This may be explained in part by the fact that 
SV5 establishes persistent non-lethal infections in infected cells, and in vivo spread of the virus 
occurs by cell-to-cell fusion. In such circumstances, the cytotoxic T cell (Tc cell) is required 
to lyse the infected cells and clear the infection. Thus, the net effect of Tc cell activity is 
preventing further spread of the virus and terminating infection. This mechanism may not be 
applicable to NDV because NDV replicates rapidly, enabling large amounts of the infectious 
virus to be released quickly from infected cells before an effective immune response can be 
made. With such an infection, the cellular-immune response is unlikely to be sufficiently rapid 
to significantly alter the peak titer of the virus achieved in the body, whereas neutralizing 
antibodies which are more successful in restricting the replication of viral infection and 
preventing the spread of virus within infected tissues is more Hkely to be protective (2). 
Furthermore, recent work with the influenza virus has demonstrated that animals rendered 
deficient in cytotoxic (Tc) or helper (Th) cell responses were able to clear the influenza virus 
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infection in a manner similar to their fiilly immunocompetent counterparts, suggesting that 
antibodies might participate in the clearance of viral infection (8). 
In conclusion, the data from this study support the concept that humoral immunity to 
NDV is a key component in the protection against Newcastle disease. Therefore, vaccination 
programs should be directed towards eliciting and maintaining high antibody levels to NDV in 
flocks of birds. 
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APPENDIX: DATA AND ANALYSIS 
Table Al. Data of blood lymphocyte blastogenesis assay (CMI), hemagglutination inhibition 
(HI) test and challenge results in birds vaccinated with either live, ultraviolet inactivated, 
SDS-treated >JDV preparation or PBS. Data are from the first trial in the first experiment. 
Birds Trial Groups Treatment CMI HI Proteaion* 
1 1 1 LVND 0.4380 10 1 
2 1 1 LNDV 1.0320 10 1 
3 1 1 LNDV 9 1 
4 1 1 LNDV 0.605 9 1 
5 1 1 LNDV 10 1 
6 1 1 LNDV 9 1 
7 1 1 LNDV 9 1 
8 1 1 LNDV 9 1 
9 1 1 LNDV 9 1 
10 1 1 LNDV 9 1 
11 1 1 LNDV 9 1 
12 1 1 LNDV 0.4880 10 1 
1 1 2 UVNDV 5 1 
2 1 2 UVNDV 7 1 
J 1 2 UVNDV 7 1 
4 1 2 UVNDV 0.6700 7 1 
5 1 2 UVNDV 7 1 
6 1 2 UVNDV 5 1 
7 1 2 UVNDV 0.5540 8 1 
8 1 2 UVNDV 0.7414 8 1 
9 1 2 UVNDV 5 1 
10 1 2 LTVNDV 5 1 
11 1 2 UVNDV 0.3350 5 1 
12 1 2 UVNDV 7 1 
1 1 3 SDSNDV 0 0 
2 1 3 SDSNDV 0.390 0 0 
3 1 3 SDSNDV 0.5190 0 0 
4 1 3 SDSNDV 0 0 
5 1 3 SDSNDV 0.3920 0 0 
6 1 3 SDSNDV 0 0 
7 1 3 SDSNDV 0.4461 0 0 
8 1 3 SDSNDV 0 0 
9 1 3 SDSNDV 0 0 
10 1 3 SDSNDV 0 0 
1 1 4 Control 0.0400 0 0 
2 1 4 Control -0.130 0 0 
3 1 4 Control 0 0 
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Table Al. (Continued). 
Birds Trial Groups Treatment CMI HI Protection* 
4 1 4 Control 0 0 
5 1 4 Control 0 0 
6 1 4 Control 0 0 
7 1 4 Control 0 0 
8 1 4 Control -0.02 0 0 
9 1 4 Control 0 0 
10 1 4 Control 0 0 
11 1 4 Control 0 0 
12 1 4 Control 0.393 0 0 
* 0=No protection, 1= protection 
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Table A2. Data of blood lymphocyte blastogenesis assay (CMI), hemagglutination inhibition 
(HI) test, and challenge results in birds vaccinated with either live, ultraviolet inactivated, SDS 
treated NDV preparation or PBS. Data are from the second trial in the first experiment. 
Birds Trial Groups Treatment CMI HI Protection 
1 2 1 LNDV 9 1 
2 2 1 LNDV 9 1 
2 1 LISIDV 9 1 
4 2 1 LNDV 10 1 
5 2 1 LNDV 11 1 
6 2 1 LNDV 9 1 
7 2 1 LNDV 1.470 10 1 
8 2 1 LNDV 0.568 11 1 
9 2 1 LNDV 0.3480 9 1 
10 2 1 LNDV 0.3424 10 1 
1 2 2 UVNDV 4 1 
2 2 2 UVNDV 4 1 
3 2 2 UVNDV 4 1 
4 2 2 UVNDV 5 1 
5 2 2 UVNDV 5 1 
6 2 2 UVNDV 5 1 
7 2 2 UVNDV 0.080 6 1 
8 2 2 UVNDV 0.395 5 1 
9 2 2 UVNDV 0.110 5 1 
10 2 2 UVNDV 0.418 4 1 
1 2 3 SDSNDV 0 0 
2 2 J SDSNDV 0 0 
3 2 3 SDSNDV 0 0 
4 2 J SDSNDV 0 0 
5 2 3 SDSNDV 0 0 
6 2 3 • SDSNDV 0 0 
7 2 3 SDSNDV 0.420 0 0 
8 2 3 SDSNDV 0.420 0 0 
9 2 3 SDSNDV 0.430 0 0 
10 2 3 SDSNDV 0.560 0 0 
1 2 4 Control 0 0 
2 2 4 Control 0 0 
3 2 4 Control 0 0 
4 2 4 Control 0 0 
5 2 4 Control 0 0 
6 2 4 Control 0 0 
7 2 4 Control 0.020 0 0 
8 2 4 Control 0.010 0 0 
9 2 4 Control 0.10 0 0 
10 2 4 Control 0.135 0 0 
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Table A3. Data of blood lymphocyte blastogenesis assay (CMI), hemagglutination inhibition 
(HE) test, and challenge results in CY-treated and CY-nontreated birds vaccinated with either 
ultraviolet inactivated NDV or PBS. Data are from the first trial in the second experminent. 
Birds Trial Groups Treatment CMI HI Protection* 
1 1 1 CY-UVNDV 0 0 
2 1 1 CY-UVNDV 0 0 
3 1 1 CY-UVNDV 0.479 0 0 
4 1 1 CY-UVNDV 0.6093 4 1 
5 1 1 CY-UVNDV 0.4868 2 1 
6 1 1 CY-UVNDV 0.51135 0 0 
7 1 1 CY-UVNDV 2 1 
8 1 1 CY-UVNDV 0 0 
9 1 1 CY-UVNDV 0 0 
10 1 1 CY-UVNDV 0 0 
1 1 2 CY-PBS 0.01 0 0 
2 1 2 CY-PBS 0.03 0 0 
3 1 2 CY-PBS 0.06 0 0 
4 1 2 CY-PBS 0.03 0 0 
5 1 2 CY-PBS 0 0 
1 1 3 C-UVNDV 5 1 
2 1 3 C-UVNDV 0.3498 6 1 
3 1 3 C-UVNDV 1.50 6 1 
4 1 3 C-UVNDV 0.759 5 1 
5 1 3 C-UVNDV 0.500 5 1 
1 1 4 C-PBS 0.06 0 0 
2 1 4 C-PBS 0.02 0 0 
3 1 4 C-PBS 0.01 0 0 
4 1 4 C-PBS -0.09 0 0 
5 1 4 C-PBS 0 0 
* 0 = No protection; 1 = protection 
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Table A4. Data of blood lymphocyte blastogenesis assay (CMI), hemagglutination inhibition 
(HI) test, and challenge results in CY-treated and CY-nontreated birds vaccinated with either 
live, ultraviolet inactivated NDV or PBS. Data are from the second trial in the second 
experiment. 
Birds Trial Groups Treatment CMI HI Protection 
1 2 1 CY-LNDV 0.5833 4 1 
2 2 1 CY-LNDV 0.5670 5 1 
3 2 1 CY-LMDV 0 0 
4 2 1 CY-LNDV 0 0 
5 2 1 CY-L>JDV 0 0 
6 2 1 CY-LNDV 0 0 
7 2 1 CY-LNDV 0 0 
8 2 1 CY-LNDV 0 0 
9 2 1 CY-LNDV 2 1 
10 2 1 CY-LNDV 0 0 
11 2 1 CY-LNDV 0.4380 0 0 
12 2 1 CY-LNDV 1.0320 0 0 
I 2 2 CY-UVNDV 0 0 
2 2 2 CY-UVNDV 0.937 0 0 
3 2 2 CY-UVNDV 0 0 
4 2 2 CY-UVNDV 0 0 
5 2 2 CY-UVNDV 0 0 
6 2 2 CY-UVNDV 2 1 
7 2 2 CY-UVNDV 0 0 
8 2 2 CY-UVNDV 0.955 0 0 
9 2 2 CY-UVNDV 3 1 
10 2 2 CY-UVNDV 0.548 0 0 
11 2 2 CY-UVNDV 0 0 
12 2 2 CY-UVNDV 0.67224 3 1 
1 2 J CY-PBS 0 0 
2 2 3 CY-PBS 0.08 0 0 
3 2 3 CY-PBS 0 0 
4 2 3 CY-PBS 0 0 
5 2 3 CY-PBS 0 0 
6 2 J CY-PBS 0 0 
7 2 3 CY-PBS 0.25 0 0 
8 2 3 CY-PBS -0.1500 0 0 
9 2 3 CY-PBS 0 0 
10 2 3 CY-PBS 0 0 
11 2 J CY-PBS 0 0 
12 2 J CY-PBS 0.078 0 •0 
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Table A4. (Continued). 
Birds Trial Groups Treatment CMI HI Protection 
1 2 4 C-LVND 0.4380 10 1 
2 2 4 C-LNDV 1.0320 10 1 
3 2 4 C-LNDV 9 1 
4 2 4 C-LNDV 0.605 9 1 
5 2 4 C-LNDV 10 1 
6 2 4 C-LNDV 9 1 
7 2 4 C-LNDV 9 1 
8 2 4 C-LNDV 9 1 
9 2 4 C-LNDV 9 1 
10 2 4 C-LNDV 9 1 
11 2 4 C-LNDV . 9 1 
12 2 • 4 C-LNDV 0.4880 10 1 
1 2 5 C-UVNDV 5 ' 1 
2 2 5 C-UVNDV 7 1 
3 2 5 C-UVNDV 7 1 
4 2 5 C-UVNDV 0.6700 7 1 
5 2 5 C-UVNDV 7 1 
6 2 5 C-UVNDV 5 1 
7 2 5 C-UVNDV 0.5540 8 1 
8 2 5 C-UVNDV 0.7414 8 1 
9 2 5 C-UVNDV 5 1 
10 2 5 C-UVNDV 5 1 
11 2 5 C-UVNDV 0.3350 5 1 
12 2 5 C-UVNDV 7 1 
1 2 6 C-PBS 0.0400 0 0 
2 2 6 C-PBS -0.130 0 0 
3 2 6 C-PBS 0 0 
4 2 6 C-PBS 0 0 
5 2 6 C-PBS 0 0 
6 2 6 C-PBS 0 0 
7 2 6 C-PBS 0 0 
8 2 6 C-PBS -0.02 0 0 
9 2 6 C-PBS 0 0 
10 2 6 C-PBS 0 0 
11 2 6 C-PBS 0 0 
12 2 6 C-PBS 0.393 0 0 
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Table A5. Analysis of variance of protection results from the four trials. 
Dependent variable: protect 
Source Degree of Sum of Mean F Value Pr> F 
Freedom Square Square 
Model 3 14.80323 4.93442 109.234 0.0001 
Error 68 3.07175 0.04517 
Corrected total 71 
Pearson Correlation Coefficients / Prob > R under Ho: Rho=0 
CMI HI 
Protection 0.4661, 0.90650 
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Table A7. Blood lymphocyte response to UVNDV in CY-treated and CY-nontreated birds 
vaccinated either with live, ultraviolet inactivated NDV or PBS. The values represent the 
average stimulation index (SI) for each bird calculated using the formula defined in the 
experimental design section. Mean SI values for each group with different superscripts 
indicate a significant difference at the P < 0.05 level. 
Simulation Index (SI) 
Groups 1 2 3 4 Average 
First trial 
CY-UVNDV 0.479 0.609 0.486 0.511 0.521' 
CY-PBS 0.01 0.03 0.06 0.03 0.032'' 
C-UVNDV 0.349 1.5 0.759 0.5 0.777' 
C-PBS 0.06 0.02 0.01 0.09 0.045*' 
Second trial 
CY-LNDV 0.583 0.567 0.778 0.511 0.610' 
CY-UVNDV 0.937 0.955 0.548 0.672 0.778' 
CY-PBS 0.08 0.25 -0.150 0.078 0.0645'' 
C-LNDV 0.438 1.032 0.605 0.488 0.640' 
C-UVNDV 0.67 0.554 0.741 0.335 0.575' 
C-PBS 0.04 -0.13 -0.02 0.393 0.070*" 
Table A8. Analysis of variance of data on cellular immune response of CY-treated bird 
experiments 
Source Degree of Sum of Mean F P r > F  
Freedom Squares Square Value 
Vaccine 2 4.64963933 2.3 ;2481966 19.86 0.001 
CY 1 0.06530983 0.06530983 0.56 0.4603 
Vaccine* CY 2 0.04235725 0.02177862 0.18 0.8353 
Error 34 3.98030912 0.11706792 
corrected total 39 8.73761553 
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Table A9. Blood lymphocyte response to UVNDV in birds vaccinated with either live, 
ultraviolet inactivated, SDS-treated NDV preparation or unvaccinated control. The values 
represent the stimulation index (SI) for each bird calculated using the formula defined in the 
experimental design section. Mean SI values for each group vvith different superscripts 
indicate a significance at the P < 0.05 level. 
Stimulation Index (SI) 
Groups 1 2 3 4 Average 
First Trial 
LNDV 0.438 1.032 0.605 0.488 0.6407' 
UVNDV 0.626 0.552 0.741 0.335 0.5751' 
SDSNDV 0.39 0.519 0.392 0.4461 0.436 ' 
C-PBS 0.04 -0.013 -0.02 0.393 0.07 
Second Trial 
LNDV 1.47 0.568 0.348 0.3424 0.7151' 
UVNDV 0.08 0.395 0.11 0.418 0.250 ' 
SDSNDV 0.420 0.42 0.43 0.56 0.457 ' 
C-PBS 0.02 0.01 0.01 0.135 0.043 b 
Table AlO. Analysis of variance of lymphocyte blastogenesis response to UVNDV in birds 
vaccinated with either live NDV, UVNDV,' SD SNDV or PB S. 
Source Degree of Sum of Mean F Pr>F 
Freedom Squares Square Value 
Vaccine 3 1.38345753 0.46115251 8 0.0005 
Error 28 1.61449216 0.05766043 
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THE ROLE OF ANTIBODIES TO NEWCASTLE DISEASE VIRUS 
POLYPEPTIDES IN PROTECTION 
Manuscript for submission to Avian Diseases 
A. D. Maraqa and D.L.Reynolds 
SUMMARY 
Studies were undertaken to determine whether passive immunization utilizing 
hyperimmune sera that were specific for Newcastle disease virus (NDV) proteins conferred 
protection against virus challenge. Six groups of 3-week-old chickens were passively 
immunized with antiserum against either HN /F, NP/P, M, a mixture of all proteins (ALL), 
intact UV, inactivated NDV, or negative sera. Blood samples were collected two days post-
immunization and the birds were challenged with Texas GB strain of NDV. Antibody titers to 
HN/F, ALL and UV-NDV were detected in the recipient birds by a hemagglutination 
inhibition (HI) test, an ELISA, and a virus neutralization (VN) test. Whereas antibodies to 
NP/P and M were detected only by ELISA, antibody titers in the recipient birds dropped by 
two dilutions (Log2) after two days post-injection. Protective immunity revealed that birds 
passively immunized with antisera against HN/F, ALL and UVNDV were resistant to the 
challenge virus, whereas chickens passively immunized with antisera against NP/P and M 
proteins and SPF sera developed clinical signs of Newcastle disease. The challenge virus was 
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recovered from all passively immunized groups. It was concluded that the presence of 
neutralizing antibodies to NDV provided protection from clinical disease but was unable to 
prevent virus shedding. 
Keywords: Newcastle disease virus, passive immunization, humoral immune response, 
protection 
Abbreviations: 
CPE cytopathic effect 
CMF-PBS calcium and magnesium free- phosphate buffered saline 
F fusion protein 
EDTA ethylenediamineteraacetic acid 
HLD50 embryo lethal dose 
ELISA enzyme linked immunosorbent assay 
IBV infectiou bronchitis virus 
m hemagglutination inhibition test 
HN haemagglutinin-neuraminidase 
L large protein 
M matrix protein 
MTT (3-[4,5-Dimethylthia2ole-2-yl], 2-5-diphenyItetrzolium bromide 
NDV Newcastle disease virus 
NP nucleoprotein 
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p phosphoprotein 
PBS phosphate buffered saline 
SPF specific pathogen fi-ee 
ST swine testicle 
SW5 Simin virus 5 
VN viral neutralization 
UVNDV ultraviolet inactivated Newcastle disease virus. 
TCID50 tissue culture infectious dose 50% 
INTRODUCTION 
Newcastle disease (ND) is a highly contagious viral disease of poultry (2). It causes 
hemorrhagic intestinal lesions, severe respiratory distress, nervous disorders, decreased egg 
production and high mortality (2). 
Newcastle disease virus (NDV) is the prototype member of the paramyxovirus family 
and is designated as PMVl. It is an enveloped virus writh negative-stranded RNA (2). The 
NDV virion contains six proteins; nucleoprotein (NP), phosphoprotein (P), matrix (M), fusion 
(F), hemagglutinin-neuramindase (HN), and large (L) proteins. The HN and F proteins are 
glycosylated and form two projections on the lipoprotein envelope of the virion. They have 
been found to play a role in neutralizing NDV in vivo and in vitro by preventing virus 
attachment and cell fusion activity, respectively (2). The M protein is located on the inner 
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surface of the envelope and provides structural integrity for the virion. The NP, P and L 
proteins are associated with genomic RNA to form the nuclecapsid (2). The role of antibodies 
to NP/P and M proteins in protection against NDV infection is unclear. 
Following vaccination with NDV, antibodies directed towards the various components 
of the virus are produced to protect the birds against ND infection (3). Although high levels of 
antibodies have always been associated with protection against ND (2, 4), reports have 
suggested that serum antibodies are not directly correlated with the resistance of chickens to 
experimental NDV challenge (7, 8, 9, 11). One study found that a low level of antibodies was 
capable of preventing infection (9), while another (11) found that chicks vaccinated with an 
inactivated NDV vaccine given intramuscularly induced little resistance despite a high 
concentration of serum antibody. Studies with other paramyxoviruses have indicated that 
neutralizing antibodies may not be sufficient to protect against the disease (16, 25). It has also 
been reported that the presence of neutralizing antibodies, although they may lessen the 
severity of disease, are unable to prevent infection (16). 
The objective of this study was to determine the role of passively administered antisera 
directed against individual NDV polj^jeptides (or whole virus) in protection. 
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MATERIALS AND METHODS 
Embryonated eggs and chickens. Specific pathogen-free (SPF) eggs (HY-Vac Co., 
Gowrie, lA) were used for virus propagation and hatching. Chicks were reared on wire-
floored cages for three weeks, and feed and water were provided ad libitum. 
Media and reagents. A solution of minium essential medium (MEM) (Life 
Technologies, Inc., Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS), 
penicillin (100 lU /ml), streptomycin (100 |J.g/ml), and fungizone (0.5 M-g/ml) was used to 
culture swine testicular (ST) cells. The MEM was used without serum as a maintenance 
media. A calcium and magnesium fi-ee-phosphate buffered saline (CMF-PBS) was used for 
washing monolayers. 
Virus strains. The lentogenic strain B1 of NDV was propagated in nine-day-old SPF-
embryonated eggs by the chorioallantoic route. The allantoic fluid was harvested and 
centrifuged at 3000 x g for 30 minutes. Then the virus was purified and concentrated from the 
allantoic fluids. 
The velogenic Texas GB strain of NDV was propagated in embryonic eggs and used 
as an inoculum at lO^ELDso/bird and used as the challenge virus (see below). 
Virus propagation and puriflcation. Newcastle disease virus purification was based 
on the method of Alexander and Collins (3). The lentogenic strain B1 of >ff)V was grown in 
9-day-old embryonated chicken eggs for 5 days at 37 C. The allantoic fluid was clarified by 
centrifiigation at 3000 x g for 30 minutes. The virus was pelleted by centrifiigation at 50,000 
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X g for 2 hours in a SW28 rotor (Beckman). Then the pellet was resuspended in 0.01 M Tris-
NaCl pH 7.2 and applied to a discontinuous sucrose gradient made from 14ml 50% w/v and 
21 ml 20% w/v in 10 mM Tris, 0.1 M NaCl, 1 mM EDTA, pH 7.4. Following centrifiigation 
for 2 hours at 50,000 x g, a visible band was observed at the sucrose gradient interface. After 
the virus band was collected and pelleted at 50,000 x g for 2 hours, the pellet was 
resuspended in PBS. The purified vims was assayed for total protein concentration using the 
Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA) and the purity was assayed by 
Coomassie blue-stained polyacryamide gel electrophoresis. The purified virus was inactivated 
by exposure to uhraviolet light for 40 minutes and evaluated to assure the loss of infectivity in 
the embryonic eggs. Then the inactivated NDV (UVNDV) was used as an inoculum at 40 |j,g 
per bird. 
Preparation of NDV proteins. The procedure for isolating M)V glycoproteins 
(HN/F), nucleoprotein and nucleocapsid associated protein (NP/P), and the matrix (M) from 
the NDV virus was performed as described previously (23). Briefly, purified NDV 
(approximately 0.5 mg/ml) was diluted 1:5 (v/v) in 4% Triton X-100 (Sigma) in 0.01 M Tris 
buffer (pH 7.2) in the presence of 1 M KCl. The solution was mixed gently at room 
temperature for 45 minutes. The suspension was centiifuged at 10,000 x g for 35 minutes, 
and a clear supernatant fluid containing HN, F and M polypeptides, and a pellet contauiing 
NP/P was obtained. The pellet was washed repeatedly in PBS and pelleted by centrifiigation at 
10,000 X g for 1 hour at 4 C. The supernatant from the 10,000 x g centrifiigation was 
centrifiiged at 200,000 x g for one hour to remove any remaining nucleocapsid or 
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incompletely disrupted virus. Then the pellet was discarded and the supernatant fluid was 
dialyzed against 0.01 M PBS for 16 hours in order to remove potassium chloride. After 
dialyzing, the matrix protein (M) was separated from the glycoproteins (HN and F) by 
centrifugation at 10,000 x g for 30 minutes. The pellet (M protein) was suspended in PBS. 
The proteins which remained in the supernatant fluid after removal of M protein were 
centrifuged repeatedly at 10,000 x g for 10 minutes at 4 C to remove any other protein 
contaminates. The purity of the collected proteins was assayed by Coomassie blue-stained 
polyacrylamide gel electrophoresis. 
Preparation of antiserum. Hyperimmune serum to purified NDV proteins were 
prepared. The separated HN/F, NP/P and M polypeptides were emulsified by mixing with an 
equal volume of incomplete Freund's adjuvant. The inoculmn was injected subcutaneously 
into 3-week-old SPF chickens (two birds per group). The chickens were boostered 2 weeks 
later and then blood was collected weekly for 5 weeks. 
Hyperimmune serum to purified ISIDV were also prepared by subcutenous injection of 
40 ng/ml of UVNDV emulsified with incomplete Freund's adjuvant into three-week-old SPF 
chickens. The chickens were boostered 2 weeks later and then blood was collected weekly for 
5 weeks. 
ELISA. An avidin-biotin dot immunobinding assay was used as previously described 
(6). Briefly, 0.12-inch nitrocellulose membrane disks (Trans-Blot Transfer Medium, Bio-Rad 
Laboratories, Hercules, CA) were cut and placed at the bottom of each of the wells of a 96-
well, flat-bottom tissue culture plate (Becton Dickinson and Company, Lincohi Park, NJ). 
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One microliter of purified NDV (100 /ml) was dotted in the middle of each disk and the 
plate was incubated over night at 37 C to dry the dot. One hundred microliters of diluent 
buffer were added to each well. Then, 100 |al of 1:100 diluted serum were added to each well 
of the first column of wells. Afterward, twofold serial dilutions were performed across the 
plate to achieve a dilution range of 1:100 to 1:204,800. Positive and negative sera were also 
included in the test. After one hour of incubation, the secondary biotinylated antibodies 
(biotinylated anti-chicken IgG, Vector Laboratories, Burlingame, CA) at a dilution of 1:5000, 
strept-avidin at a dilution of 1:2000, and the chromogen (4-Chloro-l-Naphthol; Sigma 
chemical Co., St. Louis, MO) were subsequently added. The nitrocellulose membrane was 
washed and blocked between each step. Finally, the plates were incubated in the dark until 
dark purple dots appeared against the white (nitroceUulose) background, which was 
considered a positive reaction. 
Western blot. Purified NDV was solubilized in a gel sample buffer containing 0.0625 
M Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 0.001% bromophenol blue and heated at 100 C 
for two minutes. The proteins were separated on a 10% polyacrylamide gel according to the 
procedure of Laemmli (15). The gel was electrophoresed at a constant voltage of 150 V for 
four hours. Part of the gel was stained with Coomassie brilliant blue G 250 (Pharmacia 
Biotech, Piscataway, NJ) destained with methanol, and fixed. The remaning portion of the gel 
was prepared for transfer onto a 0.45 |im nitrocellulose membrane (Trans-Blot Transfer 
Medium, Bio-Rad Laboratories, Hercules, CA) for Western blot analysis. The transfer was 
carried out in a transfer buffer consisting of 25 mM Tris, 192 mM glycine (pH 8.3) and 20% 
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v/v methanol at a constant voltage of 60 V for 4 hours. After transfer the membrane was 
stained with 0.05% Ponceau S dye (Fisher Biotech, Fisher Scientific, Fair Lawn, NJ) in 1% 
acetic acid for band visulization. The nitrocellouse membrane containing the separated 
proteins was cut into 7 mm strips and each strip was placed into an individual well on an 
immunoblotting plate. The ELISA procedure was used for developing the blot. 
Hemagglutination inhibition (HI) test. The HI test was performed as described (3). 
Briefly, twofold serial dilutions of serum were made in a 96 well, round-bottom microtiter 
plate containing 50 |il of PBS in the first row and 50 pil of NDV antigen (10 HLA units) in the 
remaining 11 rows. Serum dilutions ranged from 1:2 to 1:2048. The antigen serum mixture 
was incubated for 30 minutes at 37 C. Then, 50 |j,l of a 0.05% turkey erythrocyte suspension 
were added to each well and reincubated for 30 minutes. A positive serum, a negative serum, 
erythrocytes and antigens were also included as controls. The highest dilution of serum 
causing complete inhibition was considered the endpoint. The geometric mean titer was 
expressed as reciprocal Loga values of the highest dilution that displayed HI. 
Virus neutralization (VN) test. The virus neutralizion test was performed as 
described previously (1), except the ST cell line was used instead of chicken embryo 
fibroblasts. Briefly, 50 microliters of media were added into an empty 96-well flat-bottomed 
tissue culture plate (Coming Laboratoiy Sciences Co., Coming, NY). Another 50 }il of the 
serum sample were added into the first column. Twofold serial dilutions were made across the 
plate to achieve dilutions from 1:2 to 1:1024. One hundred tissue-culture infectious doses 
(TCIDso) of the Texas GB strain of NDV in 50 |al were mixed with equal volumes of the 
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semm dilutions. Then the plate was incubated for one hour at 37 C in a humidified 5% CO2 
incubator. Fifty nl of media without antibodies were mixed with the virus suspension for the 
virus control, and 100 fil of medium without antibodies or virus were used for a cell control. 
Positive and negative serum controls were also included in the experiment. All samples were 
tested in quadruplicate. Following a 1-hour incubation period, 100 [il of the virus-serum 
mixture were transferred into 96-well culture plates containing monolayers of a swine 
testicular (ST) cell line., and incubated at 37 C for 72 hours. The plate was examined for 
cytopathic effect (CPE) to confirm the presence of the virus. The 50% neutralizing endpoint 
(ED50) was calculated by the method of Reed and Muench (21). 
Sample collection for virus isolation. A cotton-tipped applicators were used for 
swabbing the trachea. The applicators were then placed into 2 ml a tryptose phosphate broth 
containing penicillin and streptomycin and fi^ozen (-70 C). On the day of inoculation, the tubes 
were thawed and the swabs were removed. The remaining fluid was centrifuged at 1000 x g 
for 10 minutes, and the supernatant was collected and used for embryo inoculation. Five 9-
day-old embryonated eggs per tracheal swab sample were inoculated via the chorioallantoic 
route with 0.1 ml of inculum per embryo. The eggs were incubated at 37 C for 7 days. Then 
the presence of NDV in the harvested chorioallantoic fluid was determined by 
hemagglutination (EIA) testing using 1% turkey erythrocytes. 
Experimental design. Sbc groups (10 chickens/group) of 3-week-old SPF chickens 
were passively immunized subcutaneously with 4 ml with either anti-HN/F sera, anti-NP/P 
sera, anti-M sera, a mixture of all NDV proteins sera (ALL), anti-UVNDV sera, or negative 
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SPF sera. Blood samples were collected 2 days post-immunization and the birds were 
challenged with 10^ ELDso of the Texas GB strain of NDV per bird administered 
intramuscularly. Tracheal swabs were taken at 4 days post-inoculation and used for virus 
isolation. All the chickens were observed for 14 days following challenge. Two trials were 
conducted and in each trial 10 birds per group were used. 
RESULTS 
The antibody titers of birds vaccinated with various NDV polypeptides are shown in 
Table 1. Those birds that were vaccinated with the HN/F glycoproteins and UVNDV had 
detectable levels of specific antibodies as measured by the HI, ELISA and VN tests, whereas 
birds vaccinated with NP/P and M proteins had antibodies that were detected by the ELISA 
but not by the HI or the VN tests. A combination of anti-HN/F, NP/P and M sera had 
antibodies that were detected by the HI, ELISA and VN tests. The Western blot results 
revealed that all vaccinated groups had a positive antibody response to their respective 
polypeptides to which they had been vaccinated (Figure 1). 
Table 2 displays the results of serum titers from trials 1 and 2 of the recipient birds two 
days post-administration. The results revealed that recipient birds which were passively 
immunized wath anti-HN/F sera, a combination of ALL sera, or UVNDV sera had detectable 
antibody titers as measured by the HI, ELISA and VN tests, whereas recipient birds passively 
immunized with anti-NP/P or anti-M sera had detectable antibody titers only in the ELISA 
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Table 1. Antibody titers of donor sera obtained from chickens vaccinated with NDV 
or various NDV polypeptide preparations. 
Antibody titer reciprocal Log2 
Sera"" HI® ELISA^ VN° 
HN/F 6 8 7.84 
NP 0 9 <2 
M 0 6 <2 
ALL 6 9 7.46 
UV-NDV 7 9 8.7 
^ Sera collected from birds vaccinated with HN/F, NP/P, M or UVNDV. 
® Hemagglutination inhibition-geometric mean titers expressed as reciprocal Log2. 
^ Enzyme-linked immunosorbant assay. ELISA was performed as reciprocal Log2 dilution x 
100 
° Virus neutralization assay. The neutralization titer was the reciprocal of the dilution of 
antisera which neutralized 50% of virus. 
test, and not the HI or VN tests. The antibody titers were found to be two to three Log2 
dilutions lower than the original sera used for administration. 
The challenge resuks from trials 1 and 2 are shown in Table 3. The results revealed 
that the majority of recipient birds passively immunized with anti-HN/F sera, ALL sera and 
UVNDV sera were protected from challenge. However, birds passively immunized with anti-
NP/P sera, anti-M sera and negative SPF sera developed clinical signs of Newcastle disease. 
Clinical signs of ND and/or death appeared by the third day post-challenge in birds that were 
102 
HN 
NP/P 
M 
i-f 
<*:j:«^ <-:Vx 
Figure 1. Immunoblot results of chickens vaccinated with; (1) UV-inactivated NDV; (2) 
M)V-HN and F glycoproteins; (3 ) NDV-NP/P proteins, and (4)M)V-M proteins. 
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Table 2. Antibody titers of recipient birds passively immunized with NDV hyperimmune sera. 
Trial Antibody titer Log2 
Sera^ No. m® ELISA^ VN° 
HN/F 10 3.4 5.2 4.3 
NP 10 0 6.3 <2 
1 M 10 0 3.6 <2 
ALL 10 3.8 5.3 4.6 
UVNDV 10 4 6.7 4.5 
C 10 0 0 <2 
HN/F 10 3 5.3 4.42 
NP 10 0 5.5 <2 
2 M 10 0 3.9 <2 
ALL 10 4 5 4.70 
UVNDV 10 4 6.5 4.88 
C 10 0 0 <2 
^Donor sera obtained from SPF chickens immunized with separated NDV proteins, UV-MDV 
or unimmunized SPF negative sera. 
® Hemagglutination inhibition-geometric mean titers expressed as reciprocal Log2. 
^ Enzyme-linked inununosorbant assay. Geometric mean titer expressed as reciprocal Log2 
dilution x 10. 
^ Vuiis neutralization assay. The neutralization titer was the reciprocal Log2 of the last 
dilution of antisera which neutralized 50% of the virus. 
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Table 3. Results of challenge and virus isolation from birds passively inmiunized with M)V 
antisera preparations. 
Trial Group No.^ Morbidity® Mortality % Protection^ Virus shedding^ 
HN/F 10 3/10 1/10 70% 8/10 
NP 10 0/10 8/10 . 20% 2/2 
1 M 10 0/10 9/10 10% 1/1 
ALL 10 4/10 1/10 60% 5/10 
UVNDV 10 3/10 0/10 " 70% 6/10 
C 10 0/10 10/10 0 ND^ 
HN/F 10 3/10 1/10 70% 10/10 
NP 10 0/10 10/10 0 ND 
2 M 10 0/10 10/10 0 ND 
ALL 10 3/10 0/10 70% 8 /10  
UVNDV 10 2/10 0/10 80% 7 /10  
C 10 • 0/10 10/10 0 ND 
^Number of birds in each group 
® Number of birds displaying clinical signs ofNDV. 
"^Percentage of surviving birds that did not display clinical signs of disease. 
° Number of isolations/number of samples. 
^ND: Not done. 
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not protected. The challenge virus was recovered from all groups of passively immunized 
birds. 
DISCUSSION 
Previous studies addressing the role of cell mediated immunity (CMI) in protection 
from ND have indicated that specific CMI to NDV by itself was not protective against a 
virulent NDV challenge (18). These studies have indicated that the presence of specific 
antibodies, as detenraned by the HI or the VN tests to NDV, is important in protection from 
ND. A high correlation was found between the presence of specific HI or neutralizing 
antibody response to NDV and protection. In this study, a passive immunization approach was 
used to determine whether antibodies to NDV conferred protection. In addition, the role of 
antibodies directed against specific NDV polypeptides in protection was determined. The 
results of this study revealed that birds passively immunized with anti-HN/F sera, a mixture of 
all (ALL) sera, and anti-UVNDV sera were protected from a lethal challenge of NDV, 
whereas birds passively immunized with anti-NP/P and anti-M sera were not protected. 
Similar results have been reported in other studies (12, 19, 20, 24). Umino et al. (24) found 
that passive administration of antiserum against intact NDV, or the surface glycoproteins 
HN/F, provided protection to susceptible chickens against NDV challenge. However, there 
were have been no reports of the protective role of the other NDV polypeptides. In studies 
using Simian virus 5 (SV5) Randall et al. (20) found that in viti-o neutralization was provided 
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by antibodies directed against the surface HN glycoprotein but neutralization was not 
achieved when antisera against the internal proteins NP, P or M were used. Furthermore, 
similar findings have been reported for infectious bronchitis virus (IBV). It was found that 
immunizing birds with purified nucleocapsid (N) and membrane (M) proteins of the IBV did 
not protect them against virulent challenge despite high antibody titers, whereas birds 
immunized with the surface SI glycoprotein were protected (14). 
The results of this study corroborate previous findings in which humoral immunity was 
considered a key component in protective immunity (18). Similar findings supporting the role 
of antibodies in preventing the clinical signs of ND were observed in this study. However, 
passively acquired antibodies were found to have little effect on the ability to prevent tracheal 
viral shedding. The challenge virus was detected in the majority (but not all) of passively 
immunized protected birds four days post-challenge. The differences between the two studies 
may be due to the amount of antibodies that may have been transported to the mucosal 
surface of the respiratory tract. Yoshida (26) reported that the amount of neutralizing 
antibody titers were very low in tracheal samples Srom birds that had been passively 
immunized with anti-NDV hyperimmune sera. The transport of antibodies fi-om the circulatory 
system was also different between the upper and lower respiratory tracts. The transudation of 
serum antibodies into the upper respiratory tract was reported to be very limited in chickens 
administered high-titered antiserum to avian IBV. However, transudation of antibodies to the 
lung correlated with the concentration of serum antibodies (11). Similar observations have 
been reported following influenza virus infections of neonatal ferrets. Husseini (10) found that 
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ferrets with high maternal antibodies demonstrated complete protection in their lungs, 
however, virus replication occurred in their upper respiratory tract. 
Many studies have addressed those conditions required to obtain the presence of 
antibody in the respiratory tract (7, 8, 11). Holmes (12) reported that either direct or indirect 
exposure of the respiratory tract to an antigen was necessaiy for inducing neutralizing 
antibody. In birds having maternal antibodies, it was found that the lacrimal fluid antibody 
titers ranged from 1-9% of the serum antibody titers. Following intraocular vaccination with 
live NDV the lacrimal fluid antibody titers increased significantly. The increase in antibody 
titers were attributed to local replication of NDV in the Harderian gland (22). Ewert et al. (8) 
reported that birds which had been passively immunized with antisera to NDV showed a sharp 
rise of antibodies in the trachea four days following intratracheal viral inoculation. This was 
found to be a result of transudation of antibodies from the serum which coincided with the 
course of viral pathology observed in the trachea of the infected birds. 
The importance of the presence of a local antibody response in the respiratory tract of 
NDV-vaccinated birds in protection has been documented (5, 10, 11, 12, 16). It has been 
reported that vaccination with NDV via aerosol administration protected them against 
challenge given by the respiratoiy route, but not against intramuscular challenge, whereas the 
vaccination of chickens via the airsac protected the birds against airsac challenge but not 
against intraocular route (5, 16). The replication of the virus in the respiratory tract in the 
presence of circulating antibodies may provide ample antigenic stimulation to confer "full 
protection" to the host, that is, no clinical disease or virus replication in the trachea. It was 
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found that vaccinated birds derived from matemally-iramune chickens which had been 
vaccinated with NDV were more resistant to challenge than were corresponding unvaccinated 
birds. Surprisingly, there was no difference in the serum antibody response titers between 
vaccinated and unvaccinated birds (7). 
In conclusion, the results of this study indicated the importance of the presence of 
antibodies to the HN and F polypeptides of NDV in resistance to NDV challenge. In addition, 
the demonstration of the challenge virus from the tracheas of protected birds is suggestive of 
the importance of the local immune response in protection. 
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SUMMARY 
Five continuous cell lines, swine testicular ( ST), human rectal tumor (HRT 18), fetal 
rhesus monkey kidney (MAI 04), bovine turbinate (BT) and quail tracheal (QT35) were 
evaluated and compared with chicken embryo fibroblasts (CEF) for their ability to propagate 
B1 or Texas GB strains of Newcastle disease virus (NDV). The NDV Texas GB strain was 
found to replicate in all the continuous cell lines used in this study. Only the ST and QT35 
cells produced a cytopathic effect (CPE) similar to that produced in CEF. However, the ST 
cell line remained attached while displaying CPE, whereas infected QT35 cells detatched as 
did the CEF. The B1 strain of NDV was found to replicate in ST cells, MAI 04 cells and CEF 
but with less CPE as compared to the Texas GB strain. Pretreatment with trypsin did not 
enhance CPE with either NDV strain. Sera evaluated for neutrali2dng antibody titers to NDV 
were found to be significantly higher in titers when the ST cell line was used and compared to 
CEF. A high correlation was found between microscopic examinations and MTT microassay 
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methods for determining the viral neutralization endpoint, thus suggesting the ST cell line and 
MTT assay could be used as an alternative to CEF and microscopic examination for 
evaluating neutralizing antibodies titers to NDV. 
Keywords: Newcastle disease virus, virus neutralization, continuous cell line, MTT 
assay. 
Abbreviations: 
BT bovine turbinate cells 
CEF chick embryo fibroblast 
CMF-PBS calcium and magnesium fi"ee- phosphate buffered saline 
CPE cytopathic effect 
DMEM Dulbecco's modified eagle's medium 
FBS fetal bovine serum 
EDTA ethylenediaminetetraacetic acid 
HEPES N-2 hydroy-ethylpiperazine-N'2-ethanesulfonic acid 
HRT 18 human rectal tumor cell 
MEM minimum essential medium 
MA 104 monkey kidney cell line 
NDV Newcastle disease virus 
PBS phosphate buffer saline 
QT35 quail trachea 
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ST swine testicular cell 
TCIDso tissue culture infectious dose 50% 
VNso fifty percent virus neutralization endpoint 
INTRODUCTION 
The humoral immune response to Newcastle disease virus (NDV) is commonly 
evaluated by hemmagglutination inhibition (HI), ELISA, agar gel precipitation (AGP), and/or 
the virus neutralization (VN) test (1). Conventionally, the HI test has been widely used and is 
an acceptable serological technique for monitoring antibody levels against NDV in poultry (1). 
However, a lack of correlation has been reported between serological responses, as measured 
by the HI test, and protection against virus challenge following vaccination with ND vaccines 
(6). It has been reported that the HI assay could not detect low levels of circulating antibodies 
(6). Beard and Brugh (3) indicated that neutralizing antibodies to NDV in vaccinated birds 
could be demonstrated several months aftei* vaccination, by a variety of procedures even 
though the HI titers were negative. These results suggest that a more sensitive method for 
measuring the humoral antibody response is required for NDV to predict protective immunity. 
Virus neutralization (VN) is a test used frequently to determine the ability of serum 
antibodies to neutralize the infectious agent after vaccination (5). The most commonly used 
method to evaluate neutralizing antibody titers to NDV is based on the presence or absence of 
cytopathic effect (CPE) in chicken embryo fibroblast cells (1, 2). Such an assay requires a 
114 
constant source of specific pathogen-free (SPF) embryos, and the preparation and 
maintenance of primary and secondary chicken embryo fibroblasts (CEF) (4). Additionally, 
CEFs have a limited period of use. Typically, the neutralizing endpoint is determined by a 
microscopic examination of individual culture wells and an estimation is made of the extent of 
CPE. Consequently, this methodology is time-consuming and the results have an inherent 
subjectivity in endpoint determination (7). 
Recently, several microneutralization immunoassays have been described for 
quantitating neutralizing antibody titers (7, 8, 12, 13) which have been empolyed in various 
methodologies for automation. Many assays have used an ELISA reader in place of 
microscopic examinations to obtain quantitative results. This saves time and labor, and 
produces an objective determination of a neutralizing antibody titer endpoint. 
The objectives of this study were to identify a continuous cell line capable of 
supporting NDV replication which could be used in a VN microassay and to adopt rapid 
methodology by utilizing ELISA reader technology. 
MATERIALS AND METHODS 
Media and reagents. IVGnimum essential medium (MEM), Dulbecco's modified 
eagle's medium (DMEM) (Life Technologies, Inc., Gaithersburg, MD), and Hams FIO-
medium 199 mixture (1:1) were supplemented with 10% fetal bovine serum (FBS) (AJanta 
Biological, Norcross, GA). Pencillin (100 lU/ml), streptomycin (100 |ig/ml) and fungizone 
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(0.5|ig/ml) were used to culture different cell lines. The maintenance media for propagating 
viruses or maintaining cells were the same as the growth medium but without FBS. A calcium 
and magnesium-free-phosphate buffered saline (CMF-PBS) was used for washing the 
monolayers. A solution of 0.05% trypsin supplemented with 0.53 mM 
ethylenediaminetetraacetic acid (EDTA) was used for cell passage. An MTT (3-[4,5-
Dimethylthiazole-2-yl].2-5-diphenyltetrazolium bromide; Sigma Chemical Co., St. Louis, MO) 
solution was prepared by dissolving 10 mg of MTT in 1 ml of CMF-PBS and solubilized by 
sonication. The solution was then filtered through a 0.45 |am syringe filter and stored at 4 C in 
a light-proof bottle. The HCl-isopropanol (0.04 N HCl-isopropanol) solution was prepared by 
adding 40 ml of 1 N HCl to one liter of isopropanol. Then the HCl isopropanol solution was 
stored at room temperature in a light-proof bottle. 
Viruses. The lentogenic strain Bl, B1 and the velogenic Texas GB strains of NDV 
were grown in nine-day-old embryonated SPF chicken eggs. Embryonated eggs were 
inoculated by the chorioallantoic route and incubated for 5 days at 37 C. The allantoic fluid 
was harvested and then clarified by centrifiigation at 1000 x g for 30 minutes. The infectivity 
of the virus was determined by establishing an EIDso in embryonated eggs. The allantoic fluid 
was aliquoted and stored at -70 C. 
Cell culture. Chicken embryo fibroblasts (CEF) and the following cell lines were used 
in this study: MA104 fetal rhesus monkey kidney, bovine turbinate (BT), HRT18 (human 
rectal tumor cells), swine testicular (ST) and QT35 (quail tracheal). Chicken embryo 
fibroblasts were prepared from nine-day-old SPF chicken embryos (Hy-Vac Co., Gowrie, lA) 
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and were cultured in DMEM containing 10% FBS. The MA104, HRT18 and BT cells were 
grown in DMEM, whereas the ST cells were grown in MEM medium. The FIG-199 medium 
was used to culture QT35 cells. All of these cells were grown to 80-90% confluency and 
maintained in 25 cm^ culture flasks (Coming Laboratory Sciences Co., Coming, NY) at 37 C 
in 5% CO2. Cells were passaged every 4 days using tiypsin-EDTA, and placed into new 25 
cm^ culture flasks (2 x 10'' cells) and incubated at 37 C in. 5% CO2. 
Virus inoculation. Flasks containing monolayers of either chicken embryo fibroblasts 
or one of the continuous cell lines were washed twice with their respective serum-free media 
and were inoculated with 10"* EIDso/ml (1 ml/per flask) of NDV. Following a one-hour 
adsorption period at 37 C, the cell monolayers were washed twice with their respective serum 
free media and 10 ml of maintenance medium was added. Additionally, NDV was pre-treated 
with 10 ^ig/ml of trypsin for 60 minutes at 37 C and used as an inoculum at a final 
concentration of 0.5 ng/ml (10"* EID50 /ml). Cells without vims and cells with 0.5 |ag/ml 
trypsin were used as controls. The cell culture flasks were observed daily for 5 days for 
cytopathic effects (CPEs). 
Serum samples. A number of semm samples, derived from SPF chickens previously 
vaccinated with NDV, with different antibody titers were used in this study. The sera were 
heat-inactivated at 56 C for 30 minutes and stored at -70 C until used. Based on the HI 
results, the sera were placed into low, medium and high titers groups, respectively. Another 
eight semm samples, were used to determine the effect of semm concentration on cell survival. 
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Virus titration in CEF and ST cells. Chicken embryo fibroblasts and ST cells were 
prepared in 96-well flat bottomed tissue culture plates (Coming Laboratory Sciences Co., 
Coming, NY). Ten-fold serial dilutions of the virus preparation were made in the respective 
FBS-fi:ee media. The vims titration ranged from 10"' to 10"'°. One-hundred microliters of each 
vims dilution were added per well using 12 replicate wells per dilution. The inoculated 
cultures were then incubated at 37 C for three days and examined for CPE. The TCIDso was 
calculated according to the method of Reed and Muench (10). 
Virus neutralization (VN) assay. Twelve sera samples with different HI antibody 
titers were used for assessing the VN assay. Microscopic examinations were made to 
determine the amount of CPE. Alternatively the tetrazlium dye, MTT, was used to measure 
the CPE. Fifty microliters of media were added into empty 96-well flat-bottomed tissue 
culture plates (Coming Laboratory Sciences Co., Coming, NY). Fifty microliters of the semm 
to be tested were added to the wells of the first column. Then, twofold serial dilutions were 
made across the plate to achieve a dilution range from 1:2 to 1:1024 (column 1-10). A 
solution of 100 TCIDso of the Texas GB strain of NDV, in a volume of 50 |jJ, was mixed with 
an equal volume of the diluted seram. The plates were incubated for one hour at 37 C in a 
humidified 5% CO2 incubator. A 50-til medium without semm was mixed with the vims 
suspension (column 11) for the vims control, representing a 0% neutralization. For the cell 
control, representing 100% neutralization, a medium without semm or vims was used 
(column 12). One hour following incubation, 100 |J,1 of the vims-semm mixture were 
transferred into 96-well culture plates containing ST cells or CEF monolayers and incubated 
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at 37 C for 72 hours. At 69 hours of the incubation period, a microscopic examination of the 
plate was made before adding MTT. Following that, 10 |il of MTT (10 mg/ml) were added to 
each well and the piate was reincubated for three hours. At 72 hours of incubation, the plate 
was centrifiiged at 1000 x g for 10 minutes at room temperature. The supernatant was 
removed and 100 }il of IN HCl-isopropanoI were added to each well to aid in dissolving the 
formazan crystals. The plate was shaken for 10 minutes on a plate shaker (mini-orbital shaker, 
Bellco Biotechnology, Vineland, NJ) and the cells were thoroughly resuspended by repeated 
pipetting with a micropipetiter. The absorbance of each well was measured using a microtiter 
ELISA reader (Model ELS 10, Bio-Tek Instruments, Inc., Winooski, VT 05404) at a 
wavelength of 550 nm. 
All samples were tested in quadruplicate. The average of the absorbance was 
calculated for each serum dilution, the virus control, and the cell control wells. The 
absorbance value which was used to calculate the 50% neutralizing endpoint (VN50) for each 
sera was determined as follows: 
(average absorbance of cell control without virus) + {average absorbance of virus control) 
2 
Then the average absorbance of each serial dilution was plotted for each sample tested. The 
serum dilution, which corresponded to a 50% neutralizing endpoint as calculated above, was 
determined from the neutralization curve or by using the method of Reed and Muench (10). 
Serum effect on the MTT VN microassay. The purpose of this experiment was to 
determine whether the serum had an effect on the VN assay. Fifty microliters of media were 
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added to the first 4 rows of the empty microtiter plate (Coming Laboratory Sciences Co., 
Coming, NY). An additional 50 |il of 1:2 diluted semm were added into the first well of each 
row. Twofold serial dilutions were then performed across the plate to achieve a dilution range 
&om 1:4 to 1:8190 (fi-om column 1 to column 12). Subsequently, 50 |j,l of media were added 
to the first 4 rows and 100 |al of media were added to the remaining 4 rows. The sera dilutions 
were transferred into the CEF or ST cell line in 96-well tissue culture plates and incubated at 
37 C for 72 hours. At 69 hours of incubation, MTT was added and the vims neutralization 
procedure was performed as described above. A statistical analysis was conducted to 
determine if the semm had an effect on the cells. 
Statistical evaluation. Statistical analyses were conducted using the SAS statistical 
software package (SAS Institute Inc., Cary, NC). Statistical significance was expressed as 
highly significant (P <0.01), significant (P < 0.05), or not significant (P>0.05). An analysis of 
variance (ANOVA) using Duncan's multiple comparison procedure was performed to 
determine the differences between neutralizing antibody titers as determined by the two 
methods (microscopic examination and.MTT micr.oassay) in. both CEF and ST cell lines. The 
correlation between neutralizing antibody titers for the two methods was evaluated by 
assessing the significance using the Pearson correlation coefficient (r), where r > 0 indicates a 
positive linear relationship and r < 0 indicates a negative relationship. 
To ascertain whether the presence of semm had any effect in determining the 50% cell 
survival endpoint (VN50) in CEF, multiple linear regressions were used to relate absorbance 
values to dilution, allowing different semm samples to have different intercepts. The 
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hypothesis of no serum effect was tested by comparing the fit of two regressions: one 
assuming no serum efifect and the other allowing for a serum effect using a F test. An 
ANOVA was also used to analyze the ST cell line. 
RESULTS 
Growth of Texas GB and B1 strains of NDV in CEF and continuous cell lines. 
Microscopic examinations of cell cultures infected with lentogenic B1 strain and the velogenic 
Texas GB strain of NDV revealed that the Texas GB strain replicated in all the continuous cell 
lines evaluated in this study. Replication of Texas GB strain produced distinctive CPE. 
However, only the ST and MAI 04 cell lines, in addition to the CEF, supported the B1 strain 
of NDV. Less CPE was observed when compared to Texas GB strain. No CPE was detected 
when the B1 was inoculated into the other cell lines. 
The extent of CPE induced by different NDV strains varied considerably (Table 1). 
The CPE appeared sooner with the virulent strain (Texas GB) than the B1 strain. Typically, 
cell cultures which were infected with Texas GB displayed CPE between 48-72 hours after 
infection, with the notable exception of HRT18 cells in which CPE appeared after 96 hours. 
The greatest amount of cellular destruction was observed in CEF, QT35 and ST cell lines 
infected with the Texas GB. In contrast, those cell cultures infected with the B1 strain (CEF, 
ST and MAI 04) showed less cell destruction and, at 96 hours after infection, much of the cell 
culture remained intact and not infected (Figure 1). 
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Table 1. Cytopathic effect induced by the NDV strains: Bl, Bl and Texas GB in chicken 
embryo fibroblasts and various continuous cell lines. 
Cell-^ Bl® Bl +T'^ TxGB° TxGB + T C^ C + T 
CEF + + 1  1  1  1 1  1  I I  - -
ST + + - H - H - I I  I I  - -
MAI 04 + + +++ +-H-
- -
QT35 - - 1  I I  1  1  1  I I  
- -
HRT18 - - + + - -
BT 
- -
-K- ++ 
- -
CEF = Chicken embryo fibroblast, ST = swine testicular cell line, MAI 04 = Monkey kidney 
cell line, QT35 = Quail trachea cell line; HRT18 = Human rectal tumor cell line, BT = 
Bovine turbinate cell line. 
® B1 = Lentogenic NDV strain B1 type B1. 
T = NDV strain pretreated with trypsin. 
° TxGB = Velogenic NDV strain Texas GB. 
^ C = No virus, negative control cell culture. 
+ less than 50% cytopathic effect 
++ from 60- 70% cytopathic effect 
+++ from 70- 80% cytopathic effect 
M i l  from 80- 100% cytopathic effect 
- no cytopathic effect 
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Figure 1. Cytopathic effect of NDV in the ST cell line at 96 hours post-inoculation. (A) 
unifected control monolayer (SOX). (B) ST cells infected with Bl, Bl strain of NDV 
(SOX). (C) ST cells infected with Texas GB strain of NDV (SOX). 
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Cell cultures infected with B1 and Texas GB which were pre-treated with tiypsin were 
not found to be different from the culture in which untreated viruses were used. 
Titration of Texas GB strain of NDV in CEF and ST. The Texas GB strain of 
NDV was titered in the CEF and ST cell lines. The titers of Texas GB in CEF were 10®'^ 
TCIDso/nil, whereas the titers in the ST were 10'"^^TCIDso/rnl. 
Virus neutralization assay. Results of the comparison of NDV neutralizing antibody 
titers, as determined by microscopic examination and MTT assay in both CEF and ST cell 
lines are shown in Table 2. The ANOVAs are shown in the Appendix (Table A1 and A2). 
Neutralizing antibody titers in the ST cell line were found to be slightly, but significantly, 
higher than the CEF as determined by microscopic examination or MTT-microassay. 
However, the titers determined by the two methods (microscopic examinations and MTT 
microassay) in both CEF and ST cell lines were highly correlated (r = 0.967 for CEF, r = 
0.974 for ST cell line) (Appendix, Table A3). 
Serum effect. The multiple regression data for both CEF and ST cell lines indicated 
that the relationship between absorbance value and dilution was not the same for the cells with 
serum and cells without serum (Appendix, Table A4 and A5). The estimated relationship 
indicated that cells with serum were significantly lower than cells without serum at middle 
plate dilutions (see Figure 2). 
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Table 2. Neutralizing antibody titers against NDV in 12 sera as determined by microscopic 
examination and MTT microassay in CEF and ST cell line. 
Virus neutralization titer (reciprocal Logz) 
Groups No. HI^ CEF-MICR® CEF-MTT'  ^ ST-MICR° ST-MTT  ^
1 3 4 4.06 4.33 4.59 
Low titer 2 3 3.5 3.66 4 4.36 
3 3 3.5 3.54 4 4.02 
4 3 3.5 3.56 3.66 4.7 
5 6 7.67 7.63 8 7.24 
Medium titer 6 5 6 7.63 7.5 7.09 
7 5 6 5.78 7 7.54 
8 5 7.67 6.76 7.5 7.88 
9 8 9.67 10.30 10.33 10.75 
High titer 10 8 9 9.16 10.33 10.05 
11 8 9 9.09 9.33 10.23 
12 8 8.67 9.52 9.33 10.34 
^ Hemagglutination inhibition titer 
® Virus neutralization titer in CEF. The 50% neutralization endpoint was determined based on 
microscopic examination. 
^ Virus neutralization titer in CEF. 50% neutralization endpoint was calculated based on MTT 
microassay. 
° Virus neutralization titer on ST cell line. The 50% neutralization endpoint was determined 
based on microscopic examination. 
^ Virus neutralization titer on ST cell line. The 50% neutralization endpoint was determined 
based on MTT microassay. 
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A. Serum eflect on the chicken embryo fibroblasts 
1.30 
1.18 
1.06 
0.94 
0.82 
0.70 
3 5 6 8 10 13 2 4 7 9 11 12 
Serum dilutions ( Log 2) 
•S— with serum ^ without serum 
B. Serum effect on the ST cell line 
1.30 
1.20 
1.10 
1.00 
0.90 
0.80 
0.70 
12 13 6 10 3 4 5 7 8 9 11 2 
Serum dilutions (Log 2) 
-S— with serum without serum 
Figure 2. The effect of the presence of serum in determining a 50 % neutralizing endpoint in: 
A. chicken embryo fibroblasts and B. the ST cell Ime. The lines represent the average of the 
absorbancies from eight serum samples. Error bars denote the standard deviation. 
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DISCUSSION 
In the present study, different continuous cell lines were evaluated to identify a suitable 
continuous cell culture system that has the capacity to titer the NDV virus and determine the 
system's potential for use in a rapid neutralization microassay. Use of the swine testicular cell 
line afforded NDV replication with observable CPE of the Texas GB strain of NDV. 
Cytopathic changes were observed after two days of cultivation and were found to be similar 
to that produced by CEF. It was also found that the ST cell line was convenient and easy to 
maintain in a 96-well plate cell culture system. 
A comparison of the capacity of the Texas GB and B1 strams of NDV to replicate and 
display CPE revealed that the B1 strain replicated in MAI 04 cells, ST cells and CEFs but with 
much less CPE as compared to the Texas GB strain. In addition, the lentogenic B1 strain of 
NDV failed to produce detectable cytopathic effects in all other cell lines evaluated (see Table 
1). Reeve and Poste (11) found that the capacity of different NDV strains to induce CPE in 
different cells was related directly to their virulence for chicks and fertile eggs. Trypsin 
pretreatment of NDV did not increase CPE in the method employed in this study. This 
suggested that there was little, if any, effect on the NDV replication cycle of the B1 or Texas 
GB strains. However, Nagai et al. (9) reported that the presence of trypsin in the culture 
media was required for efficient replication of the lentogenic strains of NDV in continuous cell 
lines. In their study, 2.5-10 }ig/ml of trypsin were used to support lentogenic strains of NDV 
replication in various cells. This represents 5-20 times more than that used in the present study 
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and may explain the difference in the results. However, Nagai et al. (9) could not apply the 
same procedure with all continuous cell lines (e.g., BHBC21-F) because the cells could not be 
maintained as monolayers if such high levels of trypsin were present in the medium. The 
present researchers' experiences were similar, thus it was elected to use a small amount of 
trypsin in order to maint^ the cell monolayer. Unfortunately, the B1 strain did not display 
CPE under these conditions. 
The ability of the ST cells to propagate Texas GB to high titer levels is an additional 
reason for utilizing the ST cell line in a virus neutralization assay. However, NDV grew to 
higher titers in CEFs than in the ST cell line. A possible explanation for this titer difference 
between CEFs and ST cells may be due to differences in the sensitivity of the cells to the 
virus. Newcastle disease virus titers in the ST cell line might be increased by adopting NDV to 
the ST cell line by increasing the number of serial passages and/or by lengthening the 
incubation time, although the latter approach might reduce the sensitivity of the test due to 
nonspecific cell death. 
Neutralizing antibody titers determined in the..ST cells w;ere significantly higher than 
their paired counterparts evaluated in CEFs (see Table 2). The difference between the ST cells 
and CEFs may have been due to the difference in the way the two cell types support virus 
growth and the fact that the ST cell line has a longer lifespan than CEFs (4). The results of 
this study also revealed that there was a high correlation found between the virus 
neutralization assay using microscopic examination and the MTT assay. However, there were 
no significant differences between the microscopic examination procedure and the MTT 
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microassay procedure for determining tlie virus neutralization titer. These results support 
using the MTT assay as an alternative to microscopic examination. The MTT microassay 
would have distinct advantages for use with large numbers of sera samples. For example, the 
results are objective and lend themselves to automation since they are obtained using an 
ELISA reader instead of visual examination. In addition, the data are easily transferred and 
analyzed by electronic means. This assay is less laborious, less time-consuming and the results 
are obtained in a short time. 
In the present study, the 50% virus-neutralizing endpoint (VN50) that was used for 
determining the viral neutralization titer in the MTT microassay was ascertained by using the 
mean absorbance of the cell control (without serum) as representing 100% neutralization. This 
method has also been used by other investigators and has been found to be an applicable 
method when measuring a large number of serum samples (12, 13). However, Haddad et al. 
(7) employed another approach for estimating the VN50 in which diluted serum without virus 
was added to the plate of the cells and used to calculate the percentage of virus neutralization 
for each serum dilution. Through this method, any serum effect which might influence the true 
value of VN50 was avoided. In the study by Haddad et al. (7), the first dilution of each serum 
was used to represent the 100% neutralization value. This method seemed to be appropriate 
for positive sera, however, there was no explanation given when a negative serum was used 
(i.e., the first dilution would not be 100% neutrali2ing). The results firom the present study 
confirmed the existence of a serum effect. It is not known firom this study how the effect of 
sera would influence the true VN50 as determined in the study. In order to determine whether 
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there is a significant efifect, an experiment utilizing paired sera samples could be evaluated by 
using the estmated value (as in this study) and a method by which diluted sera without virus, 
are incorporated into the plate design and used to determine a 100% neutralization and a 0% 
neutraliiation value. It will be important to compare the two procedures in order to determine 
whether the true value of VNso is significantly different fi'om the estimated value. 
In conclusion, the ST cell line was found to be a suitable alternative for CEF for 
diagnostic and serological assays. This cell line was easy to maintain, was more resistant to the 
toxic effects of serum, supported the growth of NDV and lent itself to adaptation with the 
MTT/ ELIS A rapid methodology. 
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APPENDIX: DATA AND ANALYSIS 
Table Al. Analysis of variance neutralizing antibody titers to NDV determined by microscopic 
examination and MTT microassy in both CEF and ST cell lines. 
Sources Degree of Sum of Mean F Prob. 
Freedom Squares Square Value > F 
Level 2 265.4808 132.7404 554.24 0.0001 
CeUline- 1 5.61995 5.619951 23.47 0.0001 
Methods 1 ' 0.49525 0.495259 2.07 0.1578 
Cell* Methods 1 0.12043 0.120430 0.50 0.4822 
Error 42 10.058941 
Table A2. Duncan multiple range comparsion between CEF and ST cell lines, and between the 
microscopic examination and MTT microassay. The mean value of each variable with asterisks 
indicates a significant difference at the P < 0.05 level. 
Groups Number of observations Mean value 
CEF 24 6.5665 
ST cell line 24 7.2508* 
Microscopic 24 6.8071 
MTT assay 24 7.0102 
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Table A3. Pearson correlation coefiBcients between the neutrali2xing antibody titers for the 
two methods (microscopic examination and ST cell line) in both CEF and the ST cell line. 
CEFMICR CEFMTT STMICR STMTT 
CEFMICR 0.967 0.982 0.973 
CEFMTT 0.967 0.980 0.963 
STMTCR 0.982 0.909 0.974 
STMTT 0.973 0.963 0.974 
Table A4. Analysis of variance representing the eflfect of the presence of serum in chicken 
embryo fibroblasts in determining the 50% cell survival endpoint (VN50). 
Source Degree of Sum of Mean F Pr>F 
Freedom Squares Square Value 
Model 12 541966.69 45163.89 22.623 0.0001 
Error 163 325402.710 1996.335 
Corrected 175 867369.4 1996.356 
total 
Table A5. Analysis of variance of the effect of the presence of serum in the ST cell line in 
determining the 50% cell survival endpoint (VN50). 
Source Degree of Sum of • Mean F Pr>F 
Freedom Squares Square Value 
Model 12 926814 77234.58 24.876 0.0001 
Error 163 506077 3104.76 
Corrected 175 143228 
total 
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GENERAL SUMMARY 
Newcastle disease (ND) is a viral disease of poultry that has economic importance 
throughout the world. The clinical disease varies in morbidity, mortality, clinical signs and 
lesions. A paramyxovirus, Newcastle disease virus (NDV) is an enveloped virus with 
negative-stranded RNA. The NDV genome encodes the proteins; nucleoprotein (NP), 
phosphoprotein and V protein (PfV), matrix (M), fiasion (F), hemagglutinin-neuramindase 
(HN) and large (L) proteins. Various types of NDV vaccines, including live attenuated, 
inactivated and recombinant vaccines, have been used successfully for reducing losses and 
providing protection from the disease (Alexander, 1991). However, ND continues to be of 
economic significance in pouhry production, requiring the development of better methods for 
its control (Bernard and Easterday,1981). 
There have been conflicting reports about the nature of the immune response required 
for protection against NDV. Although high levels of antibodies have been associated with 
protection against NDV (Beard and Bruge, 1975)-, a lack of correlation between humoral 
immune response and protection has also been reported (Allan and Gough, 1976; Gough and 
Alexander, 1973). It has been suggested that more than humoral immunity is required for 
protection (Ghumman and Bankowski, 1976; Marino and Hanson, 1986). Additionally, little is 
known about the role of cell-mediated immunity in protection. Thus, understanding the avian 
immune mechanism required for protection against NDV and identifying the polypeptides of 
NDV involved in the immune response may facilitate better protection strategies. The 
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objectives of this research were to evaluate the role of cellular and humoral immunity to NDV 
in relation to protection. 
In the first study, the effect of in ovo cyclophosphamide (CY) treatment on B and T 
cells was studied. Evaluation methods were concerned with chicken survival and growth, 
peripheral blood lymphocyte blastogenic responses to LPS (B cell mitogen) and Con A (T cell 
mitogen), antibody response and flow cytometeric analysis of blood lymphocytes. The results 
of this study indicated that in ovo CY-treatment decreased hatchability and increased mortality 
(determined at two weeks post-hatching). Blastogenesis results revealed that approximately 
40% of the birds were T-cell positive and B-cell negative at two weeks of age. Regeneration 
of B lymphocytes occurred at four and six weeks of age in a low percentage of those birds 
that were previously T-cell responsive but not B-cell responsive. 
Antibody response to NDV in those birds that had T-cell responses, but not B-cell 
responses, was severely depressed when the birds were vaccinated at three weeks of age with 
the B1 strain of NDV. Most birds failed to produce detectable specific antibodies to NDV, 
however, a low percentage from both trials were found to have low levels of HI antibodies 
one week post-booster. Birds that responded were found to be the same ones that responded 
to the LPS mitogen. The selective nature of CY suppression in humoral immune response was 
also detected in flow cytomerteric analysis. There was a significant decline or even the 
absence of lymphocytes expressing IgM in the CY-treated birds compared with untreated 
birds. It was concluded fi"om this study that the immunosuppressive effect of CY-treatment in 
the birds was reversible and recovery of the antibody producing organs occurred as early as 
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two weeks. The results also revealed the necessity for continued monitoring of B and T cell 
responses in CY-treated birds to identify those birds in which B-cell regeneration may have 
occurred. 
The second study was concerned with the role of cell mediated immunity as a key 
component in providing protection to chickens against ND. In this study, two different 
strategies were used. In the first strategy (virus treatment), NDV was treated with 4% SDS in 
which the preparation was heated to allow the virus to break into polypeptides. This 
preparation was then mixed with incomplete Freund's adjuvant and used as an inoculum to 
elicit a specific CMI response without inducing a specific NDV antibody response. Four 
groups of three-week-old SPF chickens were injected with live NDV (LNDV), UV-
inactivated NDV (UVNDV), SDS-treated NDV (SDSNDV) and PBS. The birds were 
boostered at five weeks of age and challenged one week post-booster. Blood samples were 
collected weekly for humoral and cellular immune response evaluation. 
The results of this study demonstrated that all vaccinated birds had specific CMI 
responses to NDV as measured by a MTT blastogenesis microassay. A specific antibody 
response was detected in birds vaccinated with LNDV and UVNDV, whereas an antibody 
response in birds vaccinated with SDSNDV was detected by Western blot analysis but not by 
HI test and VN assay. The resuUs of this study also revealed that only those groups of birds 
with a specific antibody response to the NDV (LNDV and UVNDV groups) were protected. 
However, birds with CMI-specific NDV responses without a specific antibody response to the 
NDV, (SDSNDV group) were not protected. The results fi"om this study suggested that the 
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presence of an NDV-specific CMI response by itself was not protective against ND. 
Additionally, the study also emphasized the importance of the protective epitopes that induce 
a specific antibody response to NDV. 
In the second strategy, the immunosuppressive agent, cyclophosphamide (CY) was 
used to deplete B cells in chickens to evaluate the importance of CMI in protection against 
ND. Groups of three-week-old in ovo CY-treated birds were vaccinated wdth either LNDV, 
UVNDV or PBS. Similarly, CY-untreated groups from the same hatch were vaccinated with 
either LNDV, UVNDV or PBS. All birds were vaccmated at three weeks of age, boostered at 
five weeks of age and challenged at six weeks of age. Blood was collected weekly for humoral 
and cellular immune response evaluation. The results from this study indicated that all of the 
birds vaccinated with LNDV and UV-NDV had specific CMI responses to NDV. Specific 
NDV-antibody responses were also detected in all of the CY-untreated birds and some of the 
CY-treated birds that were found to have a regenerated B-cell flmction at one week post-
booster. The challenge results revealed that birds that did not produce a specific antibody 
response to NDV developed clmical signs of ND, whereas the birds with specific antibodies 
neither developed clinical signs nor exhibited the presence of virus in tracheal swabs. In 
conclusion, the results from this study also suggested that the presence of specific antibodies 
is important in determining the ability of chickens to resist ND infection. Furthermore, the 
resuhs were also in agreement with other reports in which protection against Newcastle 
disease virus was demonstrated in the presence of low antibody levels (Gough and Alexander, 
1973 ). 
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The third study investigated the protective effect of humoral immunity against lethal 
ND in chickens. Specific antibodies to NDV polypeptides HN/F, NP/P, M, and whole virus 
(UVNDV) were prepared and used for passive administration. Six groups of three-week-old 
chickens were passively immunized with antiserum against either HN/F, NP/P, M, a mixture 
of proteins (ALL), intact UV-NDV, or negative sera. Blood samples were collected two days 
post-immunization and the birds were challenged intramuscularly with lO^ELDjo Texas GB 
strain of NDV. The serological results revealed that the antibodies firom donors birds had a 
positive antibody response to their respective polj^eptides as determined by the Western blot 
analysis. In the recipient birds, antibody titers to HN/F, ALL and UVNDV were detected by 
the HI, ELISA and VN tests, whereas antibodies to NP/P and M were detected by ELISA but 
not by the HI and VN assays even though the antibody titer was very high as determined by 
ELISA. The level of antibody titers in the recipients was found to be between two and three 
dilutions (Loga) lower than the titers in the donor sera. This was hypothesized to be due to the 
dilution effect of the serum when distributing itself throughout the body. 
Studies in protective immunity revealed that passive administration of antiserum raised 
against HN/F glycoproteins, ALL proteins, and intact UVNDV provided susceptible chickens 
protection when they were exposed to a virulent NDV challenge by the intramuscular route. 
On the other hand, birds that had been passively immunized with antisera against NP/P or M 
proteins and SPF sera developed clinical signs of ND or died. Neurological signs and/or death 
were detected by three days post-challenge. The virus was recovered at four days post-
challenge from the trachea of the majority of passively immunized recipient birds. This study 
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indicated that the presence of neutralizing antibodies to NDV, even at low titers, was 
successful in protecting chickens from the clinical disease but not from NDV infection. 
Although the movement of antibodies from the circulation to the upper respiratory 
tract in passively immunized birds has been well documented (Russell, 1993), the transport 
amount of antibodies has been very low (Holmes, 1973). Furthermore, the local immune 
response in the respiratory tract was found to be influenced by the type and the class of the 
antibody produced. The protection of the respiratory tract correlated well with an increased 
level of the secretory IgA. Passively immunized mice injected intravenously with polymeric 
IgA anti-influenza antibodies were protected against nasal challenge, whereas an intravenous 
injection of similar virus neutralizing doses of anti-influenza IgG did not reduce virus shedding 
in the majority of infected mice (Renger and Small, 1991a). This was correlated with the 
amount of antibodies that was transported into the respiratory tract. In addition, it has been 
reported that polymeric IgA was transported ten to one-hundred fold more efBciently than 
IgG on the mucosal surface of the respiratory tract (Renger and Small, 1991a). 
In conclusion, the results from this study indicated the importance of the presence of 
specific antibodies to the HN and F polypeptides of NDV in protection from NDV challenge. 
In addition, the demonstration of the challenge virus in the trachea of challenged birds may be 
an indicator of the importance of the local immune response in protection. 
The purpose of the fourth study was to find a suitable continuous cell line capable of 
supporting NDV replication which could be used for an ND viral neutralization assay when 
using MTT in a 96-well plate microassay. In this study, five continuous cell lines (MAI 04, 
139 
BT, HRT18, QT35 and ST cells) were evaluated and compared with CEFs for their ability to 
propagate B1 or Texas GB strains of NDV. The Texas GB strain was found to replicate in all 
continuous cell lines used in this study. Only the ST and QT35 cells produced CPE similarly 
to that produced in CEF. The most distinctive of CPE emerged between 48 and 72 hours in 
the ST, QT35 and CEF. In addition, high titers of MDV were detected in the ST cell line as 
well as the CEFs. These observations provided a rationale for utilizing the ST cell line as an 
alternative to CEFs for virus neutralization assay. In contrast, the B1 strain of NDV was 
found to replicate only in the ST and MA104 cell lines in addition to the CEFs. Less 
discernible amounts of CPE were observed in those cell lines when compared to the Texas GB 
strain. At 96 hours, many of the cell monolayers were still intact and not infected. 
A comparative study was performed using paired serum samples to determine NDV 
neutralization titers in CEFs and ST cells using an MTT microassay. Additionally, a 
conventional microscopic examination was performed and the neutralizing antibody titers of 
each sample were compared with those measured by the MTT microassay procedure. The 
results from this study revealed that neutralizing antibody titers in the ST cell line were 
slightly, but significantly higher than in the CEFs as determined by either microscopic 
examination or MTT-microassay. However, the titers determined in both CEF and ST cell 
lines by the two methods were highly correlated. 
The results from this study suggested that the ST cell line can be a suitable alternative 
for CEFs in NDV VN assays. This cell line was easy to maintain, more resistant to the towc 
effects of serum and supported the growth of NDV with adequate CPE. In addition, the 
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MTT-microassay procedure could be substituted for a microscopic examination when 
evaluatmg neutralizing antibody titers to M)V. This method is less laborious, saves time, and 
is convenient for a large number of serum samples. In addition, the results are obtained by 
objective rather than subjective methods and the data are easily transferred and processed by 
electronic methods. 
In conclusion, a technique was developed for inducing B-cell ablation in chickens by in 
ovo cyclophosphamide injection. A colorimetric blastogenic microassay for detecting specific 
cellular immune responses to NDV was also developed and implemented. These techniques 
were applied to determine the role of cell mediated immunity in protection against NDV as 
well as the role of antibodies to NDV polypeptides in protection. In addition, the 
quantification of neutralizing antibodies to NDV in ST cell line was evaluated using a 
colorimetric 96-well plate microassay. Finally, this study revealed the importance of antibodies 
as a key component in protection. 
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